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ABSTRACT
Coronaviruses infect a diverse range of animals from birds to pigs and
cats to humans. Coronaviruses employ RNA-based replicative processes and as
such are genetically adaptable to acquire novel host ranges. A coronavirus from
one species can jump to another by shifting its entry requirements. As we
learned from the Severe Acute Respiratory Syndrome (SARS) pandemic, this
shift in species can have detrimental consequences. Thus, it is imperative that
we understand the virus-host interaction during the entry process.
This dissertation focuses on host entry factors that influence human
coronavirus entry. Recently, a new class of proteases, the type II transmembrane
serine proteases, was shown to cleave the spike glycoprotein on human
coronaviruses, readying the virus for entry into the target cell. I explored the role
of this protein in a cell culture mimic of the human respiratory tract, the primary
site of infection. Using Calu-3 cells, I discovered that endogenous
Transmembrane Protease Serine Subtype 2 is required for optimal SARS
coronavirus entry. At physiological levels, this protease does not function
redundantly with other known protease activators of SARS coronavirus, but
rather multiple proteases may be necessary for virus entry. Additionally, this
protease typically resides in a distinct cell surface microdomain from the host
cellular receptor. However, viral binding triggers the relocalization of the
xiii

protease to the same microdomain as the receptor, possibly allowing it to cleave
the glycoprotein immediately after receptor binding.
While proteases are a key host cellular factor in coronavirus entry, there
are other necessary factors. In this document, I briefly explore unknown host
cellular factors that contribute to cellular cytotoxicity during another human
coronavirus, Netherlands strain 63, infection. Finally, I look into how the host may
protect itself from infection by stimulating a host immune response. In all, this
expands our understanding of the various host factors that influence coronavirus
entry.
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CHAPTER ONE
LITERATURE REVIEW
1.1 Introduction
Viruses are one of the scourges of modern medicine. Despite our
increased understanding of them over the past century, little can be clinically
done to combat their pathology. Preventing viral infections remains our best
defense against these microbes. The value of public health measures aimed at
preventing the spread of a virus was best demonstrated in the Severe Acute
Respiratory Syndrome (SARS) outbreak of 2003-2004. SARS was found to be
due to a coronavirus (CoV). Though CoVs have been studied since virology’s
infancy, relatively little is known about human CoVs (HCoVs). HCoVs are known
to cause mainly respiratory infections, ranging from mild to the severe form of
SARS-CoV.
Most likely, another pathogenic HCoV will emerge from the bat population
(Ren et al 2008). Approximately twenty percent of the worldwide mammalian
species is bats and they are widely distributed across the world (Dominguez et al
2007). Recent explorations into the virome of bats in the eastern United States
identified numerous novel CoVs, in accordance with other studies describing the
discovery of numerous SARS-like CoV in bats around the world (Balboni et al
2012, Brandao et al 2008, Donaldson et al 2010, Lau et al 2005, Ren et al 2006,
1
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Rihtaric et al 2010, Yuan et al 2010) Rihtaric et al 2010, Yuan et al 2010).
SARS-like CoVs are not the only HCoVs to have their origin in bat CoVs; recently
evidence demonstrated the HCoV 229E emerged from bat reservoirs in Ghana,
with their most recent common ancestor diverging about 200 to 300 years ago
(Graham & Baric 2010, Pfefferle et al 2009). Given our understanding of the
prevalence of circulating CoVs in bats and their history of emergence into human
population, one recent review concluded that “the question of emergence of
another pathogenic human CoV from bat reservoirs might be more appropriately
expressed as ‘when’ instead of ‘if’.” (Graham & Baric 2010)
This dissertation will focus of CoV entry into the human respiratory tract,
with an emphasis on host cellular factors utilized during this process. To
understand the current state CoV knowledge, one must understand the path
studies into human infections by CoV have taken. Therefore, the first section of
the dissertation will explore CoV history in depth in order to demonstrate the
ever-evolving impact of CoV discovery on the understanding of human
pathology.
1.2 CoV History
To understand the history of CoVs, a brief explanation of the time period in
which seminal discoveries were made needs to be made. At the time of the
Influenza pandemic of 1918, the etiology of the disease was ascribed to bacteria,
not a virus. The term virus has been in use describing disease since at least the
last late fourteenth century, having been originally derived from the Latin word for
poison (Harper 2012). In the late nineteenth century, observations by Ivankjlar
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and Bejerekjerkje on filterable agents causing plant diseases marked the
beginning of our modern use of the word virus. However, not until the 1920s was
it understood that viruses are “obligate parasites in the sense that their
reproduction is dependent upon living cells” although it was still debated if the
reproduction took place inside the host cell (Rivers 1927). Compounding the
issue was that often viruses, such as measles, were recovered from patients
along with numerous bacteria, making it unclear which microbe was the true
etiologic agent. As stated by T. M. Rivers in 1927, “It will be difficult for the best
trained workers…to progress rapidly in this field.” (Rivers 1927) But shortly
thereafter, the first virus later to be known as a CoV was isolated, the Infectious
Bronchitis Virus (IBV) (Beaudette 1933, Beaudette 1937). Described as “gasping
disease” this first description provides a foreboding glimpse into CoV’s most
infamous member, SARS-CoV (Weiner 1987). However, in addition to the
respiratory tract, CoVs can also infect other parts of the body. This was seen with
the discovery of Murine Hepatitis Virus (MHV) around 1950 (Gledhill & Andrewes
1951). At first, MHV-CoV was thought to be two separate viruses. The namesake
caused hepatitis in mice, but four years prior to the first publication on MHV,
another strain of MHV-CoV was isolated from mice with flaccid paralysis. This
strain, now known as MHV-JHM (after the Harvard pathologist J.H. Mueller),
causes encephalomyelitis and extensive demyelination (Bailey et al 1949,
Cheever et al 1949).
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The two strains of MHV-CoV were found to cause very different diseases
in mice. MHV-CoV caused liver lesions, which were previously attributed to
infection with Bacillus piliformis (Gledhill & Andrewes 1951). Infection with MHVCoV differed from human hepatitis viruses, known at the time, mainly in its
“lability and short incubation period”. The virus was found in the liver, kidneys,
blood, feces, and urine of infected mice. Although some neurologic symptoms
were reported, they were nothing as severe as the JHM virus. JHM was isolated
from mice that spontaneously developed flaccid paralysis of their hind limbs
(Bailey et al 1949, Cheever et al 1949). Further passage through mice revealed
that the virus caused neurological symptoms such as ruffled fur and paralysis.
Interestingly, the original authors noted that demyelination only occurred in the
central nervous system and not on any peripheral nerves. In addition to the
neurologic symptoms, the mice also have focal necrotic liver lesions. Infection
with JHM proved ultimately fatal.
After the discovery that a murine virus could cause such massive
destruction throughout the body, it was hypothesized that the virus may explain
similar diseases in humans. Thus began the investigation whether MHV-CoV or a
similar virus causes human disease, a search that lasted over fifty years. Initially,
experiments focused on finding antibodies against MHV-CoV in human sera. In
1964 Hartley, et al found that human sera contained complement-fixing
antibodies against MHV-CoV (Hartley et al 1964). They concluded that the
antibodies were specific to a virus and not a mouse or liver protein. However,
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they acknowledge that it is possible that the antibodies are actually directed
against an unknown human virus that is similar to MHV-CoV. But at the time,
they did not know of any human viruses similar to MHV-CoV, but that was soon
to change.
In the mid-1960s, papers published on novel viruses cultivated from the
human respiratory tract included the discovery of HCoVs (Hamre & Procknow
1966, Tyrrell & Bynoe 1966). The isolation of these viruses was possible
because of novel cell culture techniques using organ cultures. Most of these
viruses were recovered from humans exhibiting mild upper respiratory tract
infections. In one case, the viruses were used to infect volunteers, and they
produced a “cold” fulfilling the majority of Koch’s postulates (Tyrrell & Bynoe
1966). While multiple strains of HCoVs were described, only two, named OC43
(organ culture isolate 43) and 229E (from student specimen 229E), were studied
in depth because of the difficulty in culturing HCoVs (Hamre & Procknow 1966),
a problem that continues today. Epidemiologic evidence suggests that
approximately one-third of common colds are due to 229E-CoV and OC43-CoV
(Tyrrell et al 1993, Vabret et al 2003).
In a 1967 paper by McIntosh et al. compared the electron micrographs of
229E-CoV, IBV, and Influenza virions (Figure 1) (McIntosh et al 1967). They
noted the similarity between IBV and 299E-CoV, most notable the “club-shaped”
surface projections. This observation, also noted by other virologists, led a group
of leading virologists to propose naming this new group of viruses as
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“coronaviruses” based on their “appearance, recalling the solar corona” (Tyrrell et
al 1968). Thus, IBV, MHV-CoV, and the discovered HCoVs were united as CoVs.
The remaining decades of the 20th century yielded many new CoV family
members, although no novel HCoVs. Rather, the impact of CoVs on human
disease was thought to be through infection by MHV-CoV or a closely related
virus. As MHV-JHM is a demyelinating disease, it was hypothesized that MHVJHM or a similar virus might cause the perplexing human demyelinating disease
multiple sclerosis (MS). Studies into similarities between the CoVs led to the
identification of primary serologic groups, first described in 1974 and updated in
Table 1. As noted in the 1974 review, OC43-CoV is more similar to MHV-CoV
than to the other HCoV 229E-CoV. Supporting the relationship between human
and murine CoVs, researchers noticed in early studies that human sera is
reactive against MHV-CoV. Thus, it seemed reasonable that a virus very similar
to MHV-CoV may be the elusive etiologic agent of MS.
Two seminal papers published around 1980 supported the hypothesis that
a CoV was responsible for MS. The first paper, by Tanaka et al. described CoVlike particles in the perivascular regions of MS patients’ brains (Tanaka et al
1976). Following up on that discovery, Burks et al. reported the isolation of two
CoVs from brain homogenates of MS patients passaged intracerebrally through
mice (Burks et al 1980). Additionally, MS patients had serum antibody titers to
the novel CoVs that were higher than control patients. Although the original
paper reported that the two CoVs were not strains of MHV-CoV, Weiss, et al
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Figure 1. Negatived Stained Electron micrographs comparing the morphology of
HCoV-229E (3), IBV (4), and Influenza virions (5). Staining may alter membrane
morphology. Magnification 192,000X
Table 1. Representative Coronaviruses. There is a provisionally named group of
deltacoronaviruses found in wild aquatic birds.
Genus

Species

Host

Alphacoronavirus

Transmissible gastroenteritis virus
Porcine respiratory coronavirus
Feline infectious peritonitis virus
HCoV-isolate 229E
HCoV-Netherlands isolate 63

Pig
Pig
Cat
Human
Human

Betacoronavirus

Severe acute respiratory syndrome-CoV
Murine hepatitis virus
HCoV-Organ culture isolate 43
Bovine CoV

Human
Mouse
Human
Cow

Gammacoronavirus

Infectious bronchitis virus

Bird
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reported that the two viruses did share more homology to MHV-CoV than either
of the known HCoVs (Weiss 1983). Additionally, the virus was only propagated in
murine cell lines, not ones of human origin. Despite the seemingly murine origin
of the viruses, one of the two was used to successfully infect primates, measured
in viral replication and histologic pathology (Murray et al 1992, Murray et al
1997). However, controversy remained surrounding these findings, as other
groups reported no association between the isolates and MS (Fleming et al
1988). The investigation into a possible CoV cause of MS continued into the 21st
century with the finding that HCoVs were capable of infecting neural cells in vitro
and a preferential association of OC43-CoV with MS brain samples (Arbour et al
2000). While the controversy has not been resolved, the emergence of SARSCoV in 2003 advanced CoV research in a new direction.
The common view that HCoVs caused only mild upper respiratory
infections, or perhaps neurologic disease, dramatically shifted when a novel CoV,
SARS-CoV was identified as the cause of the Severe Acute Respiratory
Syndrome. SARS-CoV first became known worldwide when the Chinese Ministry
of Health informed the World Health Organization of an outbreak of severe
respiratory syndrome of unknown etiology that began in Guangdong providence
in 2002 (CDC 2003). By March of 2003, nearly 300 people in eleven countries
had suspected SARS (CDC 2003), with that number rising to near eightthousand before the outbreak was contained. Thanks to effective public health
measures, the spread of the virus was contained and a pandemic of
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unimaginable proportions was avoided. SARS-CoV had a mortality rate of
approximately ten percent, while the 1918 Influenza pandemic mortality rate was
approximately two and a half percent (Taubenberger & Morens 2006).
Very soon after the outbreak was announced to the world, the CoV
responsible was identified (Drosten et al 2003). Unlike previously discovered
HCoVs, SARS-CoV was easily grown in cell cultures and it exhibited a cytopathic
effect on those cells (Drosten et al 2003, Ksiazek et al 2003). Part of the reason
SARS-CoV was so quickly identified compared to previous HCoVs was the use
of modern molecular techniques and confirmation by electron microscopy.
Polymerase Chain Reaction (PCR) was used to characterize the genome and
comparisons between known viruses and the novel SARS-CoV were done using
existing records (Drosten et al 2003).
Using molecular techniques, two more novel HCoVs have been
discovered since SARS-CoV. The first of these viruses was isolated from a
clinical pediatric sample in the Netherlands, number 63 (NL63-CoV) (van der
Hoek et al 2004). This virus was not as pathologic as SARS-CoV; rather it was
more similar to the more historic HCoVs. Epidemiologic studies have shown
NL63-CoV to be slightly more prevalent than OC43-CoV or 229E-CoV, despite
following the same seasonal pattern of infection (Talbot et al 2009). The clinical
presentation is primarily a lower respiratory illness, although there can be some
upper respiratory tract involvement (Oosterhof et al 2010, Talbot et al 2009). The
virus has been correlated with the clinical condition croup (van der Hoek et al
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2005). Despite the typical mildness of the illness, there have been some reported
fatalities (Oosterhof et al 2010). Interestingly, despite the clinical, antigenic, and
genetic differences between NL63-CoV and SARS-CoV, they share the same
host cellular receptor, which will be discussed later (Hofmann et al 2005, Li et al
2005).
The second novel HCoV to be discovered was isolated from an elderly
man in Hong Kong, giving rise to the name HKU1-CoV (Woo et al 2005). Little is
known about HKU1-CoV, partly because of its fastidious growth in tissue culture.
However, recently a group reported success in culturing the virus on human
ciliated airway epithelial cell cultures (Pyrc et al 2010).
Both of the HCoVs discovered in the last eight years are not technically
newly emerged viruses. Studies into archived clinical samples have identified
NL63-CoV as far back as 1981 and HKU1-CoV in 1995 (Goes et al 2011, Talbot
et al 2009). These examples indicate that there may be many more HCoVs
currently circulating, undiscovered, throughout the human population. Given the
current state of scientific technology, both in molecular diagnostics and improved
cell cultures, we are poised to expand the CoV field considerably. It is imperative
that we take action to further understand HCoVs, not only to characterize
currently occurring viral infections, but also to prepare ourselves against future
pandemics waiting to emerge from zoonotic reservoirs.
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1.3 CoV Structure
In addition to identifying new CoVs, the last fifty years of research resulted
in a greater understanding of CoVs on a molecular level. A coronavirion is
comprised of four main structural proteins. As seen in Figure 2, the positivesense RNA genome is coated in nucleocapsid protein. The viral envelope
primarily contains membrane protein, along with the spike protein (S) and
envelope protein. Some CoVs have an additional protein in their viral envelope, a
hemagglutinin esterase (de Groot 2006). The focus of this dissertation will be on
S, as it is the primary determinant of host cell tropism and viral entry. Previous
work on MHV-CoV demonstrated that S is responsible for spread of the virus to
various tissues throughout the body (Schickli et al 2004). Recent work on the
emergence of SARS-CoV demonstrated that S mutagenesis results in the jump
across species from bat to civet cat to human infection (Li et al 2006a, Li et al
2006b, Sheahan et al 2008a, Sheahan et al 2008b). In all numerous studies have
demonstrated the importance of S recognizing the host cell receptor for entry and
viral tropism (Das Sarma et al 2000, de Haan et al 2006, Schickli et al 2004,
Tusell et al 2007).

Figure 2. Depiction of CoV. A single coronavirion with the structural proteins
highlighted.
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1.3 CoV S Structure and Function
The S of CoVs exists as a trimer extending twenty nanometers from the
viral envelope (Lin et al 2004, Neuman et al 2006). There are approximately
eighty S on one virion (Beniac et al 2006, Neuman et al 2006). Each S monomer
consists of two subunits referred to as S1 and S2 (Figure 3) (Sturman & Holmes
1984, Sturman et al 1985). These subunits are divided based on their
functionality and a cleavage site described in detail later in the text. S1 contains
the receptor binding domains (RBDs) of the spike, important for recognition and
interaction with the host cell. Recently, it has been observed that CoVs possess
RBDs either near their N-terminus or C-terminus. It has been suggested that
there is some modularity to these RBDs in that they could be exchanged
between different CoVs and thus alter virus tropism (Graham & Baric 2010).
Indeed, recent evolutionary data supports the idea that the S1 subunits of various
CoVs originally came from the same origin and diverged over time (Li 2012, Wu
et al 2012).
The S2 region consists of a fusion peptide, two heptad repeat regions, a
transmembrane region, and a region extending into the viral core. The primary
function of the S2 region is to mediate membrane fusion between the viral and
cellular membranes post-receptor binding by S1. Once the S1 region binds the
receptor, it dissociates from the S2 region. It is supposed that the dissociation of
S1 exposes the fusion peptide, allowing for insertion into the host cellular
membrane. Along with exposing the fusion peptide, removal of the S1 region also
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Figure 3. Linear depiction of S monomers. The two subunits of S (1 and 2) are
represented, including the four primary regions of S2 (FP = fusion peptide, HR =
heptad repeats, and transmembrane). The two cleavage sites with spike are
shown as red triangles. Although a trimer, S is depicted as a monomer for ease
of visualization. Additionally, the general N-terminal and C-terminal receptor
interacting domains are indicated, despite that most CoV S only contains one or
the other.
frees the refolding of S2 such that the two heptad repeat regions come into
contact forming a six-helix bundle (Figure 4) (de Groot et al 1987, Supekar et al
2004, Xu et al 2004). This refolding brings together the opposing membranes,
facilitating fusion. This type of membrane fusion protein is not unique to CoV S,
rather it is classified as a class I fusion protein and is typical of glycoproteins from
other viruses such as Influenza Virus, Human Immunodeficiency Virus, and
Ebola Virus (Bullough et al 1994, Chan et al 1997, Harrison 2008, Malashkevich
et al 1999, Weissenhorn et al 1997, Wilson et al 1981).
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Figure 4. Spike mediated fusion. Upon encountering the cell-bound receptor, S1
detaches from S2, exposing the fusion peptide within S2. The fusion peptide can
then insert into the cell membrane. Through a series of conformational changes,
the heptad repeats (HR1 and HR2) fold upon each other, bringing the viral and
cell membranes in close proximity and eventually joining the membranes through
the formation of a six-helix bundle (6-HB). Note: Drawing not to scale.
Although the primary responsibility for the S2 region is membrane fusion,
the intra-virion tail of S2 is also important during other parts of the viral life cycle.
The S2 tail is responsible for interacting with the CoV membrane protein to
facilitate S incorporation into the virion (de Haan et al 1999, Godeke et al 2000).
Palmitoylations of this region of the MHV-CoV S2 are important for this
interaction, which results to incorporation into the virion, as well as for the rapidity
with which the six-helix bundle forms (Bos et al 1995, Chang & Gombold 2001,
Chang et al 2000, Shulla & Gallagher 2009, Thorp et al 2006, Ujike et al 2012).
Overall, S functions to bind the host cellular receptor and fuse the viral
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membrane with the host cellular membrane to allow for delivery of the viral
genome and subsequent replication.
1.4 ACE2: SARS-CoV and NL63-CoV Receptor
Only three years after the discovery of Angiotensin Converting Enzyme 2
(ACE2), it was identified as the cellular receptor for SARS-CoV (Donoghue et al
2000, Li et al 2003). Until that point, research into ACE2 focused on its role in the
renin-angiotensin system. It was shown that ACE2 was capable of modifying
Angiotensin I into a form unable to be converted to Angiotensin II (Vickers et al
2002). Thus ACE2 induced opposite effects of angiotensin converting enzyme
(ACE) including vasodilation (Imai et al 2007). Additionally, ACE2 plays a critical
role in regulating heart function (Crackower et al 2002). However, in 2003 Li et al.
published the first report on ACE2 as the receptor for SARS-CoV (Li et al 2003),
expanding the breath and interest in ACE2 research. Further studies on ACE2
revealed a role for the molecule in protection from acute lung injury (Imai et al
2005, Kuba et al 2005), indicating that its role in viral pathogenesis may be more
complex than simply acting as a receptor.
Li et al., elegantly demonstrated that ACE2 transfected into cells was the
determining factor for whether the cells were permissive for SARS-CoV infection
(Li et al 2003). In a series of experiments, they showed that the S1 subunit of
SARS S was capable of binding to ACE2 and that the interaction of S with ACE2
was specific to that molecule and not the similar ACE (Li et al 2003). Thus, ACE2
was a binding factor for SARS-CoV to host cells. In order to demonstrate that
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ACE2 is a functional receptor for SARS-CoV, capable of triggering membrane
fusion, they infected cells expressing ACE2 with SARS-CoV and blocked
replication specifically with anti-ACE2 antibodies (Li et al 2003). After the
discovery of NL63-CoV, it was also shown that ACE2 is a functional receptor for
that HCoV as well (Hofmann et al 2005). This shared receptor is surprising given
the dramatically different pathology of the two viruses as well as the fact that
evolutionarily they are quite distinct.
Despite the differences between SARS-CoV and NL63-CoV, they both
interact with the same regions on ACE2 (Li et al 2007, Wu et al 2009).
Crystallography has revealed that the receptor binding domains (RBDs) of the
two viruses contact ACE2 on what the authors termed “viral binding hotspots”,
depicted in dark blue in Figure 5 (Li et al 2005, Wu et al 2009). In addition to the
two viruses being so distinct in terms of infection and evolution, the RBDs of the
two viruses also differ significantly. Shown in red in Figure 5, the NL63-CoV RBD
is formed of three loops while the SARS-CoV RBD is a larger beta sheet (Li et al
2005, Li et al 2006b, Wu et al 2009). Recent evidence suggests that the two
RBDs shared a common evolutionary ancestor but then structurally diverged.
After this evolution into different structures, they then functionally converged to
both bind ACE2 (Li 2012). It is possible that despite binding the same region of
ACE2, these differences RBD interactions could explain some of the differences
in pathology between the two viruses (Wu et al 2011).
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Figure 5. Viral binding hotspots on ACE2. Receptor binding domains of HCoVNL63 (left) and SARS-CoV (right) are depicted in association with ACE2. The
motifs highlighted in red directly interact with the receptor. The dark blue regions
on ACE2 indicate the viral binding motifs.
1.5.1 Proteolysis of CoV S
For S to execute its functions, the protein must be structurally freed to
undergo extensive conformational changes after receptor binding and expose the
fusion peptide. While produced as monomers, S is proteolytically processed
during and after virus production (Sturman & Holmes 1984, Sturman et al 1985).
This creates a thermodynamically metastable arrangement, allowing for
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refolding. Cleavage may occur at multiple steps in the virus lifecycle (Figure 6),
but as cleavage primes S for refolding the most successful timing for cleavage is
close to the trigger, being receptor-binding (Matsuyama et al 2005). However,
this cleavage was not the first one described. Rather, the only CoV cleavage
known until recently was between S1 and S2.

Figure 6. Proteolytic events during the CoV lifecycle. The CoV S can be cleaved
during various locations including during assembly (1), transit to the target cell
(2), on the target cell surface (3), or upon acidification of the endosome (4). Note:
Drawing not to scale.
As the HCoVs were extremely difficult to study, until recently MHV-CoV
served as the prototypic CoV for research. MHV-CoV S is readily cleaved during
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the virus production and transit through the Golgi apparatus (Sturman & Holmes
1984, Sturman et al 1985). A paper by de Haan et al. in 2004 confirmed what
had long been supposed, that a furin-like enzyme is the primary protease in
producer cells (de Haan et al 2004, Luytjes et al 1987). However, that paper went
on to show that inhibition of proteolysis did not affect viral infectivity. Rather,
cleavage of S into S1 and S2 was only required for cell-cell fusion, or syncytia
formation (de Haan et al 2004). This interesting finding suggests that different
proteases, and therefore different cleavage, have varying impacts on S fusion.
In addition to the S1/S2 cleavage site, a second proteolytic site in some
CoVs has been recently described. This site, known as S2’ because of its
location within the S2 region, was originally recognized in infectious bronchitis
CoV (IBV-CoV) (Yamada & Liu 2009). Two groups confirmed that this site is
relevant for SARS-CoV entry as well by introducing a furin cleavage site at the
homologous location in SARS-CoV S (Belouzard et al 2009, Watanabe et al
2008). This introduced furin cleavage site allowed for SARS-CoV S entry without
additional proteases (Watanabe et al 2008). These studies indicate that multiple
cleavage sites, and perhaps multiple proteases, are important for proper
proteolysis of SARS-CoV S for entry.
One protease capable of cleaving SARS-CoV S is trypsin (Matsuyama et
al 2005). Exogenously added trypsin experimentally represents the multiple
proteases present in the human respiratory tract that could cleave S during
transit to the target cell. Despite being able to cleave SARS-S, trypsin addition is
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detrimental to virus entry if added in the absence of receptor (Matsuyama et al
2005). It is currently hypothesized that receptor binding provides the ideal S
conformation for proteolytic enhancement of entry. Perhaps cleaving S far in
advance of encountering the receptor allows for premature refolding of the
heptad repeat domains into a six-helix bundle. Without the fusion peptide
inserted into a host receptor, this conformational change would not only be
useless for membrane fusion but also render the S no longer capable of
mediating infection because six-helix bundle formation is irreversible (Fig 4).
Currently, the most important proteolytic events for virus-cell fusion take
place during viral entry. Soon after the discovery of SARS-CoV, and the
realization that SARS-CoV S is uncleaved in mature virions, it was discovered
that inhibitors of cathepsin L reduced SARS-CoV entry (Simmons et al 2005).
Cathepsin L is a protease localized within endosomes and activated upon
acidification. In addition to endosomal proteases, more recently cell surface type
II transmembrane serine proteases (TTSPs) have also been found to cleave
SARS-CoV S (Bertram et al 2011, Glowacka et al 2011, Kam et al 2009,
Matsuyama et al 2010, Shulla et al 2011). TTSPs are discussed in detail in the
next section.
Multiple proteases with redundant virus entry functions make it difficult to
discern which proteases are necessary for viral entry into human tissues.
Additionally, some CoVs do not require any known protease for their entry,
despite the necessity of cleavage for class I fusion proteins. This difficulty is
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perhaps most recognized by the fact that the presumed proteolytic activation of
NL63-CoV, is entirely unclear. NL63 S is uncleaved after virus production and
entry was not affected by preventing endosomal acidification or by cathepsin
inhibitors (Huang et al 2006, Pyrc et al 2007). This exemplifies the fact that there
is much still unknown about HCoV entry and S cleavage in particular.
1.5.2 TTSPs
While the cellular receptor triggers some of the changes in S that result in
membrane fusion, S must also undergo proteolysis to allow for the
conformational changes necessary for fusion. As discussed earlier, there are
multiple proteases capable of cleaving SARS S. This dissertation will focus on
one such protease, the transmembrane protease serine subtype 2 (TMPRSS2).
A member of the TTSP family, and thus residing on the cell surface, this protease
is known to cleave the glycoproteins of multiple viruses (Table 2) (Bottcher et al
2006, Chaipan et al 2009, Shirogane et al 2008). While other TTSPs are capable
of cleaving SARS S. research has shown that TMPRSS2 augments entry to the
greatest degree (Bertram et al 2011, Glowacka et al 2011, Shulla et al 2011).
First described in 1997 (Paoloni-Giacobino et al 1997), a role for
TMPRSS2 in normal physiology has remained elusive. Despite being expressed
in a variety of tissues, TMPRSS2 knockout mice developed normally (Kim et al
2006). The most notable feature of TMPRSS2, aside from its function in viral
glycoprotein cleavage, is its role in prostate cancer development (Vaarala et al
2001b). While TMPRSS2 does not directly play a role in tumorigenesis, the

22
Table 2. Human Type II Transmembrane Serine Proteases and Viruses with
Cleaved Proteins
Subfamily
HAT/DESC

Hepsin/TMPRSS

Name

Viruses affected

Human airway trypsin-like (HAT
or TMPRSS11d)
Differentially expressed in
squamous cell carcinoma gene
(DESC)
TMPRSS11a
HAT-like 2
HAT-like3
HAT-like4
HAT-like5

Influenza, SARS-CoV

Hepsin
TMPRSS2
TMPRSS3
TMPRSS4
Mosaic serine protease largeform (MSPL)
Spinesin
Enteropeptidase

Influenza
Influenza, metapneumovirus

Matriptase

Matriptase
Matriptase-2
Matriptase-3
Polyserase-1

Corin

Corin

SARS-CoV

Influenza, SARS-CoV

androgen-responsive promoter elements of TMPRSS2 are fused to ETS
transcription factor genes, such as ERG (Tomlins et al 2005). The gene fusion is
found in the majority of prostate cancers (Vaarala et al 2001a). However, these
studies have not delineated a role for TMPRSS2 in normal tissues. Besides
being abundantly expressed in the prostate, not a typical site of viral infection,
TMPRSS2 is also expressed in the respiratory tract (Bertram et al 2012, Vaarala
et al 2001b). Not surprisingly, a number of respiratory viruses have been
screened for TMPRSS2 activation of their glycoproteins (Table 2) (Bertram et al
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2011, Bottcher et al 2006, Chaipan et al 2009, Glowacka et al 2011, Matsuyama
et al 2010, Shirogane et al 2008, Shulla et al 2011).
As first reported in 2006, TMPRSS2 can cleave the hemagglutinin (HA) of
certain strains of influenza, leading to their increased replication, including the
highly pathogenic 1918 strain (Chaipan et al 2009). Studies into SARS S
cleavage were first published in 2010 by Matsuyama et al. who overexpressed
TMPRSS2 in vitro and discovered that increased levels of the protease resulted
in greater cell death, an indication of increased viral replication (Matsuyama et al
2010). Shulla et al. confirmed and expanded this finding by noting that TMPRSS2
specifically increases SARS-CoV entry using pseudotyped reporter assays
(Shulla et al 2011). TMPRSS2 cleavage of S does not only allow for increased
viral entry, but also contributes to immune evasion. By cleaving S from the
surface of an infected cell, TMPRSS2 releases S fragments that can block virusneutralizing antibodies (Glowacka et al 2011). Hence the in vivo infection process
may be heavily influenced by TMPRSS2 and related family members, both at
virus entry and release, and in pathogenesis and immune evasion.
As mentioned earlier, other TTSPs are also capable of cleaving human
respiratory viruses, and studies comparing the cleavages due to different TTSPs
are enlightening. Studies into Human Airway Trypsin-like Protease (HAT or
TMPRSS11d), has provided details concerning member-specific proteolytic
properties (Bertram et al 2011). In the context of influenza HA cleavage, HAT has
a broader cleavage capacity than TMPRSS2, proteolyzing HA both in virus-
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producing cells and in progeny viruses bound to target cell receptors (BottcherFriebertshauser et al 2010). Thus HAT, not TMPRSS2, is the more relevant
protease operating on influenza at the virus entry stage. In the context of SARSCoV and S cleavage, HAT again exhibits a broader cleavage capacity than
TMPRSS2, making it so that HAT can cleave and enhance S-mediated virus
entry either in virus-producing cells or on the surface of virus-target cells
(Bertram et al 2011). However, overexpressed TMPRSS2 bypasses the
requirement for endosomal acidification and therefore cathepsin activation
(Matsuyama et al 2010, Shulla et al 2011), but HAT does not similarly replace
cathepsins in SARS-CoV entry (Bertram et al 2011). Thus a further dissection of
the various TTSP substrate specificities will be necessary to precisely identify
those most relevant to virus infection, and efforts in this regard are continuing.
For example, the first paper to examine TTSPs in the context of SARS entry
found that TMPRSS11a was capable of slightly enhancing SARS S bearing
pseudoparticles (Kam et al 2009). Subsequent findings indicated that, while
TMPRSS11a was capable of modestly increasing SARS entry at low levels of the
protease, TMPRSS2 was a more potent activator of entry (Shulla et al 2011).
Most recently, various TTSPs including TMPRSS3, TMPRSS4, TMPRSS6, and
Hepsin, have been evaluated, yet none have exceeded TMPRSS2 in augmenting
SARS-CoV entry (Bertram et al 2011, Glowacka et al 2011). Other candidate
TTSPs worth testing in SARS-CoV entry assays are MSPL and TMPRSS13, as
they have been found to cleave certain influenza Has (Okumura et al 2010).
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Overall, the field of TTSP cleavage of respiratory virus glycoproteins leaves
many more avenues for exploration.
In addition to cellular receptors and proteases, CoVs undoubtedly
encounter other host proteins during their entry. Just as the role of TTSPs lay
undiscovered for the first fifty years of HCoV exploration, there are most likely
other proteins impacting CoV entry that await discovery. In addition to further
exploring the role of TMPRSS2 in SARS-CoV entry, I also aimed to identify
unknown host factors that impact HCoV entry. These proteins could assist in viral
entry, similar to ACE2 and TMPRSS2, or they could alert the host to the invader,
as seen for other viruses. My objective was to answer the question of how a virus
recognizes the ideal target cell, enter that cell, and how the host cell may
respond to this invader. I set out to answer this question by first delineating the
role of endogenous TMPRSS2 in SARS-CoV entry into human respiratory cells.
My second aim was to identify novel host factors used by NL63-CoV for entry.
Thirdly, I explored the possibility that HCoV entry may trigger host immune
responses.

CHAPTER TWO
METHODS
2.1 Cloning
To create a recombinant MHV-CoV expressing the ectodomain of NL63CoV S, I started by PCR amplifying the desired portion of pCDM8-NL63-CoV-S
and introducing flanking AvrII and NdeI sites. The forward primer was
GCCTAGGGTTCTTCACCTGCAACAGCAACGC and the reverse primer was
CAGCGCATATGTGTTCAGCAGCTTCAGGTCGACG. The PCR product was
ligated into the pGEM-T vector system for further amplification and confirmation
of insert by NotI digestion. The pMH54-EFLM vector containing the MHV
recombinant virus expressing firefly luciferase was digested first with AvrII and
SbfI to remove the entire MHV S gene. It was subsequently digested with NdeI to
create a fragment encoding only the transmembrane and endodomains of MHV
S. A three-way ligation was performed to create pMH54-EFLM-NL63Secto. The
sequence was confirmed and the single point mutation found corrected with sitedirected mutatgenesis. To create the recombinant virus, the construct was
linearized by PacI digestion then in vitro transcribed using the Ambion
mMessage mMachine kit. Feline FCWF cells were infected with MHV-A59 and
subsequently the recombinant transcripts were electroporated into them. The
electroporated cells were overlaid on either murine 17Cl1 cells or human CaCo2
26

27
cells for selection of recombinant viruses. After three days, syncytia were
apparent on positive control rMHV-CoV infected 17Cl1 cells and virus produced
was collected.
After creation of pMH54-EFLM-NL63Secto, I isolated the gene encoding
the chimeric spike and placed it in an expression vector to confirm protein
expression. To accomplish this, I PCR amplified the chimeric spike with primers
adding an NcoI site and a BamH1 site. The forward primer was CCATG
GGTCTGTTCGTGTTTATTCTATTTTTGCCCTCTTGC and the reverse primer
was GGGATCCGGCTGTGATAGTCAATCCTCATGAGAGGAAATATTATG. After
amplifying the PCR product in pGEM-T, it was inserted into pTMI. As this vector
does not contain an epitope tag, the chimeric spike was also PCR amplified out
of pMH54-EFLM-NL63Secto by primers, which restored the NL63 S NheI site
after the signal sequence and created a KpnI site. The reverse primer also
mutated the stop codon and removed twelve amino acids from the endoplasmic
tail unnecessary for function to allow for optimal epitope tag expression. The
forward primer was GGCTAGCCTTCTTCACCTGCAACAGCAACG and the
reverse primer was CAGGTACCGTCCTGGTGTCCTCCATACTCATC. After
amplifying the PCR product in pGEM-T, it was inserted into pCDM8-NL63-S that
contained a signal sequence and c9 epitope tag.
To create an NL63 S with reduced fusion activity, I changed the
phenylalanine at position 878 to alanines. To do this I introduced mutations using
site-directed mutagenesis. The forward primer was
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CTGGAGGACCTGCTGGCCAGCAAGGTGGTG and the reverse primer was
GGTCACCACCTTGCTGGCCAGCAGGTCCTC. The mutation was confirmed by
gene sequencing done at ACGT incorporated.
The Fc fusion constructs were created in two ways. Both required the S
sequence to be removed from the starting vector using NotI and ClaI. The
PCEP4-N-CEACAM-Fc was digest first with BamHI and NotI. That fragment was
subsequently digested with ClaI. A three-way ligation then joined the S fragment
with the vector containing the Fc sequence. For SARS-S1 the forward primer
(introducing a NotI site prior to the signal sequence) was
GCGGCCGCAGCCATGCCCATGGGGTCTCTGCAACCGCTGGCCACCTTGTA
CCTGCTG. The reverse primer (introducing a ClaI site and splice donor site)
was ATCGATTAATTAATACTTACCTGTCTTCTGGCTGGTGGAGGCGAG. For
NL63-S1 the forward primer (introducing a NotI site prior to the signal sequence)
was GCGGCCGCAGCCATGCCCATGGGGTCTCTGCAAC. The reverse primer
(introducing a ClaI site and a splice donor site) was
ATCGATATACTTACCTGTATTCCGGGGCCGCACG. The two RBD-Fc
constructs were not created by amplifying a sequence from another plasmid.
Rather, I had the genes constructed for us by GenScript. This allowed us to use
codon-optimized sequences with any possible cryptic splice donor sites altered
(see Appendix for sequences). In addition to creating NotI and ClaI sites, I also
introduced a BclI site after the signal sequence and a PacI site after the splice
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donor site. This will allow any future constructs to be inserted between BclI and
PacI, negating the need for a three-way ligation.
To determine if NL63-CoV S contained any mutations, I harvested RNA
from infected CaCo2 cells using the RNeasy Mini Kit by Qiagen. Portions of RNA
were subsequently amplified using One-Step SuperScript Reverse TranscriptionPCR kit for Long Templates by Invitrogen. After confirming the length of the
cDNA, they were sequenced by ACGT incorporated.
To confirm that the shRNA targeting TMPRSS2 were specific, I created
shRNA resistant forms of TMPRSS2. As one of the shRNAs (sh263) targeted
outside of the cloning region, I only mutated the TMPRSS2 plasmid to alter the
sh10516 target site. Using site-directed mutagenesis, I altered five nucleotides
that resulted in five amino acid differences (T56A C57G T58C T59C A61T). The
forward primer used was
GGTGTCACRACGGACAAGAAGTTTTCGTCACCAAAGAAATGCGACATATCG
GACGCCCC. The reverse primer used was
CCACAGTGATGCCTGTTCTTCAAAAGCAGTGGTTTCTTTACGCTGTATAGCC
TGCGGGG. The mutations were confirmed by gene sequencing done at ACGT
incorporated.
2.2 Cell Culture
Most of the studies done used human Calu-3 cells grown in Ham’s
F12/Dulbecco’s modified Eagles Media (DMEM) with 10% fetal bovine serum
(FBS), supplemented with non-essential amino acids, sodium HEPES, L-
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glutamine, penicillin, streptomycin, and gentamycin. Other cell lines used
included CaCo2 (grown in DMEM with 10% FBS, sodium HEPES, penicillin and
streptomycin), A549 (grown in F12 with 10% FBS, sodium HEPES, penicillin and
streptomycin), MRC-5 (grown in Eagle’s Minimum Essential Media with 10%
FBS, sodium HEPES, penicillin and streptomycin), 16HBEo- (grown in Ham’s
F12/Dulbecco’s modified Eagles Media (DMEM) with 10% fetal bovine serum
(FBS), supplemented with non-essential amino acids, sodium HEPES, Lglutamine, penicillin, streptomycin, and gentamycin), 293T/293T-EBNA cells
(grown in DMEM with 10% FBS, sodium HEPES, L-glutamine, penicillin, and
streptomycin), HeLa cells (grown in DMEM with 10% FBS, sodium HEPES, Lglutamine, penicillin, and streptomycin), and LLC-MK2 (grown in 1:1 Hank’s
Minimum Essential Media and Earle’s Minimum Essential Media with 10% FBS,
sodium HEPES, penicillin and streptomycin ). 293T cells expressing hACE2 were
provided by Shibo Yang (New York Blood Center, NY).
Both Calu-3 and 16HBEo- cells were differentiated on an air-liquid culture
for some assays. Cells to be differentiated were seeded as a submerged
monolayer on 0.4 micron transwell inserts (Costar) for at least one week until
tight junctions had formed, assessed by electrical resistance measurements.
After confluence was reached, the media from the apical chamber was removed.
The basolateral media was replaced every two days until cells were deemed
ready for any given assay. Typically, cells were allowed to differentiate for one
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week on the air-liquid interface, at which time a difference in cell morphology
could be observed by light microscopy.
Most experiments requiring transfection of plasmids used the Calcium
Phosphate method. Plasmids were diluted in TE buffer and mixed with calcium
chloride prior to addition to double concentration HEBs buffer. After five minutes
of incubation at room temperature, the mixture was added to cells. Occasionally,
the PEI transfection reagent was used to create VSV and HIV pseudoparticles. In
this method, DNA was diluted in high pH DMEM lacking antibiotics. PEI was then
added to the diluted DNA, mixed, and incubated for twenty minutes prior to
addition to the cells.
Pseudoparticles were used to transduce cells either with a reporter virus
or for introduction of shRNAs. For reporter pseudoparticles, the thirty microliters
of virus was added to cells in 96 well plates for one hour at 37C. After one hour,
seventy microliters of complete media was added to the cells. For HIV
pseudoparticle assays, cells were lysed in reporter lysis buffer (Promega) 48
hours after transduction for luciferase readings. VSV-based pseudoparticles were
lysed after 20 hours. For the creation of shRNA knockdown cells or shRNA
resistant cell lines, virus was added to cells in a 10cm plate in minimal media for
one hour. After one hour, the virus was replaced with complete media. The cells
were allowed to grow for one to two more days before media containing
puromycin was used to select transduced cells.
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Cells producing the Fc containing proteins were initially made using
transduction as described for shRNA cells. However, they were subjected to
selection with both G418 and hygromycin B. To harvest protein from these stable
producer cells, the cells were grown to near confluence in 225cm flasks. The
complete media above the cells was removed and the cells were thoroughly
washed with PBS to remove any residual FBS. Subsequently, approximately 25
milliliters of serum-free media was added to the cells. After two days, this media
was collected, clarified, and stored at -20C. Cells were allowed to “recharge” with
complete media for one day prior to repeating the process. Typically, cells would
not survive more than one or two repetitions of this process. Once sufficient
media containing the Fc proteins had been collected, usually 500-1000 milliliters,
the fluid was passed through a HiTrap column prepacked with Sepharose Protein
A by GE continually using a dialysis pump at 4C. After all of the fluid had passed
through the column, it was rinsed with PBS. Proteins were eluted from the
column using 0.1M glycine pH 2.7 into Tric-HCl pH 9.5. The proteins were then
dialyzed into PBS.
To assess cell surface TMPRSS2 and ACE2, I used immunofluorescence.
For immunofluorescence on 293T cells, they were first seeded on fibronectincoated coverslips then pcDNA3.1-ACE2 and pCAGGS-TMPRSS2 were
cotransfected with PEI for one day. Immunofluorescence on Calu-3 cells differed
slightly in that the cells were not transfected. Rather they were allowed to grow
on the coverslips for at least two days. Then the cells were fixed in 3.7%
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formaldehyde in 0.1M PIPES pH 6.8 and blocked in 10% normal donkey serum.
Primary antibodies were diluted in block solution and allowed to bind to cells.
After one hour the cells were thoroughly washed and secondary antibody (again
in block solution) was added for thirty minutes. Cells were again washed, and
then mounted on coverslips with Fluoro-Gel by EMS. Images were taken using a
Deltavision Deconvolution microscope and analyzed by Imaris.
2.3 Biochemical Assays
Samples for western blotting were suspended in 1x laemmli buffer and
heated to 95C for 5 minutes prior to addition to the selected SDS-PAGE gel. For
non-reducing samples, a buffer lacking beta-mercaptoethanol was used. Gels
ranged from eight to ten percent acrylamide depending on the size of the protein
of interest. The samples were run in the gel for approximately 45 minutes at
200V. After the proteins were sufficiently resolved according to their molecular
weight, judging by a visible protein ladder, the contents of the gel were
transferred to a membrane, either nitrocellulose or PVDF, for 1 hour at 100V or
12 hours at 42V, respectively. Membranes were blocked in 5% milk in TBST for
one hour. Primary and secondary antibody staining was done in 2.5% milk for at
least one hour. As the secondary antibodies were conjugated to horseradish
peroxidase, staining was visualized using Pierce enhanced chemiluminescence
reagents either on x-ray film or a digital imager.
To analyze proteins capable of binding to one another, I used
immunoprecipitation. Protein G magnetic beads were allowed to bind with the
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capture antibody (Fc tagged proteins) for one hour. Excess antibody was washed
and cell lysate were added to the bead:antibody complex. Solution was rotated
overnight at 4C. Unbound proteins were washed three times from the
bead:antibody:protein complexes. After final wash, proteins were eluted from
beads using 1x laemmli reducing buffer.
To assess cell-surface proteins, I labeled them with biotin and purified
them using streptavidin magnetic beads. To begin, I chilled the cells for fifteen
minutes at 4C on ice and rinsed with ice-cold PBS. Immediately prior to use, I
made a solution of 1mg/ml sulfo-NHS-LC-Biotin from Piece in PBS. The biotin
was added to the chilled cells and allowed to attach at 4C on ice. After one hour,
the biotin was removed and ice-cold 100mM glycine solution was used to rinse
the cells and quench excess biotin. The cells were also washed twice with PBS.
Cells were then lysed and clarified at 1000g for ten minutes at 4C. Clarified
lysates were added to streptavidin beads and allowed to adhere overnight at 4C.
Beads containing the bound biotinylated-proteins were then rinsed five times in
lysis buffer before being resuspended in 1x reducing laemmli buffer.
Expanding upon the biotinylation assay, I used detergent resistant
membrane flotation to isolate proteins within lipid rafts. Similar to the biotinylation
assay I chilled the cells for fifteen minutes and rinsing with ice-cold PBS. Prior to
biotinylation, I added pseudoparticles to the cells and allowed them to enter for
one hour at 37C. Cells were then chilled again and fresh 05.ug/ml biotin reagent
was added for 30 minutes at 4C on ice. After quenching, rinsing, and lysis the
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cells were further disrupted by passage through an insulin needle five times. The
lysate was mixed with 1:1 with a 90% sucrose solution, then added to the bottom
of a SW41 Beckman tube. On top of the 45% solution, a 35% sucrose solution
and then a 5% sucrose solution were carefully added. The gradient was spun for
approximately eighteen hours at 30,000rpm in a Beckman SW41 rotor at 4C.
After spinning, fractions were removed from top to bottom and streptavidin beads
added. Any proteins in the fractions were allowed to bind to the beads overnight
while rocking at 4C. The bead:protein complexes were then washed in 0.1x lysis
buffer three times prior to resuspension in 1x reducing laemmli buffer.
2.4 Virological Assays
Most of the assays in this dissertation utilized single-cycle pseudoparticle
transductions as entry mimics. Both HIV- and VSV- based pseudoparticles were
created by transfecting a plasmid containing the envelope protein of interest
along with a plasmid containing a genome lacking a gene for an envelope
protein. Two days post-transfection, the media above cells were collected and
clarified through a 0.45 micron filter. Pseudoparticles were either directly applied
to target cells, or pelleted under a 30% sucrose cushion at 70,000rpm for 30
minutes in a Beckman TLA100.3 rotor. Pelleted pseudoparticles were
resuspended in 1x laemmli buffer and subjected to western blot analysis.
To assess the role of cathepsins on SARS-CoV entry, I used bafilomycin
to inhibit endosomal acidification. Calu-3 cells, both shControl and TMPRSS2
knockdown, were pretreated with bafilomycin or the vehicle control DMSO at
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37C. After two hours, the pretreatment was replaced with identical concentrations
of bafilomycin also containing SARS S pseudoparticles at 37C. After two more
hours, the treatment was removed and cells were rinsed with saline three times.
After approximately twenty hours, the cells were lysed and luciferase was
measured.
To determine if trypsin cleavage can “rescue” bafilomycin treated or
TMPRSS2 knockdown cells, I added exogenous trypsin to our bafilomycin assay.
The modified protocol began with thirty minutes of pretreatment with bafilomycin
of DMSO at 37C followed by ten minutes on ice at 4C to chill the cells.
Pseudoparticles were added to the cells and allowed to bind on ice at 4C for
thirty minutes, still in the presence of bafilomycin. The unbound pseudoparticles
were removed and dilutions of pre-warmed trypsin added to the cells at room
temperature for five minutes. The trypsin was then replaced with complete media
and cells were left overnight at 37C. After approximately twenty hours, the cells
were lysed and luciferase was measured.
To assess if NL63-CoV could produce plaques on CaCo2 cells, a standard
plaque assay was performed. Dilutions of virus were made in serum free media.
Then the dilutions were added CaCo2 cells. Virus was allowed to enter cells for
one hour at 37C. Viral inoculums were replaced with DMEM with 2% FBS and
0.5% noble agar. After five days of infection, the cells were fixed and stained with
0.1% crystal violet in saline. Plaques were then counted by eye.
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As plaque assays measure infection by assessing cytopathic effects, I
also measured infection by molecular methods. As NL63-CoV is a positive sense
RNA virus, infection can be determined using reverse-transcription PCR. Using
the dilutions of virus made for the plaque assay, I infected a parallel plate of
CaCo2 cells. Cells were overlaid with complete media and left at 37C. After five
days, RNA was isolated using the Qiagen RNeasy Mini kit using envelope gene
specific primers. From that RNA, a one step RT-PCR was performed using
Invitrogen’s One-Step RT-PCR kit and envelope specific primers. PCR products
were subjected to agarose gel electrophoresis to determine the presence of
amplified envelope gene.
To create virus like particles, equal amounts of plasmids containing the
MHV structural gene (M, E, N) were co-transfected into cells with or without a
plasmid containing the selected S gene. Two days after transfection, media
above the cells was collected and clarified. The virus like particles were pelleted
over a 30% sucrose cushion at 70,000rpm for 30 minutes in a Beckman
TLA100.3 rotor. The pellet was resuspended in 1x laemmli buffer and subjected
to western blot analysis.
To confirm that Fc conjugated proteins were capable of binding ACE2 on
the cell surface, they were used to block entry of SARS S-coated
pseudoparticles. Dilutions of the Fc proteins were made in serum free media
(5nM to 5uM, except NL63-RBD did not include higher concentrations because
stock protein concentration was not high enough). Media above 293-ACE2 cells
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were aspirated and the dilutions of Fc proteins were added to cells along with
pseudoparticles (VSV G-coated particles served as control). After one hour, the
mixtures were replaced with complete media. After two days, cells were lysed
and luciferase was measured.
To assess if Fc-tagged proteins induced cytokine release, I used
differentiated Calu-3 cells. After confirming their differentiation by electrical
resistance measurements, I added the proteins (or positive control TNF) at
three different concentrations to the apical chamber. Proteins were allowed to
attach to cells for one hour at 37C. After one hour, the proteins were removed
and the basolateral media was refreshed. The cells were allowed to produce
cytokines for six hours at 37C prior to harvesting the basolateral media and
performing apical washes. Samples were immediately added to plates for
enzyme-linked-immunosorbance assay using the eBioscience Ready-SET-Go!
Kit.

CHAPTER THREE
RESULTS
3.1 Endogenous TMPRSS2 on Calu-3 cells
Previous work has demonstrated that TMPRSS2 can enhance SARS-CoV
entry into cultured cells overexpressing the protein (Matsuyama et al 2010,
Shulla et al 2011). However, the question remains if endogenous TMPRSS2 is
required for entry into the human respiratory tract. This question is important to
understanding the true role for proteases in SARS-CoV infection in vivo.
Investigations into the presence of TMPRSS2 in the various tissues have shown
the presence of TMPRSS2 mRNA in the human lung (Vaarala et al 2001b) and
the protein was detected by immunohistochemistry in primate lung tissue
(Matsuyama et al 2010). However, the amount of TMPRSS2 protein in the
respiratory epithelium has not been explored.
To begin assessing endogenous TMPRSS2 protein levels, I explored its
expression in multiple cell lines by western blotting. At the time, no validated
antibodies for endogenous TMPRSS2 were commercially available. Thankfully,
the Lin lab graciously donated their recently constructed antibody against the
extracellular domains of TMPRSS2 for our use, which had been validated using
immunohistochemistry (Chen et al 2010). In Figure 7, multiple cell lines were
examined for mature TMPRSS2 expression (approximately 28 kDa). Calu-3
39

40
cells were found to contain the highest level of mature TMPRSS2. To ensure that
the antibody was specific for TMPRSS2, 293T cells transfected with
TMPRSS11a (9), TMPRSS11d (10) and ACE2 (11) serving as negative controls
were probed alongside 293Ts transfected with TMPRSS2 (+) as a positive
control with beta-actin serving as a loading control.

Figure 7. Endogenous TMPRSS2 in human cell lines. Cells were counted and
approximately equal cell numbers were lysed prior to loading for western blot.
Left, lysates of indicated cell lines were probed for TMPRSS2. 293T cells were
transfected with various amounts of TMPRSS2-containing plasmid prior to lysis.
Right, relative amount of endogenous TMPRSS2 in Calu-3 cells compared to
TMPRSS2 plasmid transfected into 293T cells.
Previous work in our lab had determined an ideal range of protein
expression that enhanced SARS-CoV entry into transfected 293T cells (Shulla et
al 2011). For endogenous TMPRSS2 to assist in SARS-CoV entry, it was
assumed that similar levels of endogenous protein must be found comparable to
transfected levels. Figure 7 (right side) shows the comparison between
endogenous TMPRSS2 in Calu-3 cells and protein levels from various amounts
of transfected TMPRSS2 in 293Ts. The amount of endogenous TMPRSS2 was
within the range capable of increasing SARS-CoV entry into cells.
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Two of the cell lines found to express endogenous TMPRSS2, Calu-3 and
16HBEo-, can differentiate in culture to form mimics of the bronchial epithelium.
As SARS-CoV enters via the respiratory epithelium, these cells are ideal cell
culture surrogates for our studies. Recently, Kawase et al. determined that the
mRNA levels of TMPRSS2 in Calu-3 cells are comparable to those found in
human lung tissue (Kawase et al 2012), providing further evidence that Calu-3
cells are the appropriate cell line for studying endogenous TMPRSS2 in the
human respiratory tract in vitro.
3.2 SARS S-mediated transduction into Calu-3 cells
Before using these cell lines in further studies of SARS-CoV S-mediated
entry, I needed to determine a pseudoparticle transduction system in which
SARS S introduced measurable levels of the luciferase reporter. Two commonly
employed pseudoparticle transduction systems were evaluated for suitability
(Figure 8).
The HIV-based pseudoparticle system has been used quite often for
studies into SARS S-mediated entry (Nie et al 2004, Simmons et al 2004). It is
easily pseudotyped with high levels of SARS S. However, there are some
drawbacks to this system as reporter expression depends on integration into the
HIV genome of the target cell. Some cells are resistant to this process, and even
those that are susceptible take a relatively long time to express adequate levels
of the protein for detection. Probably because of those limitations, the HIV-based
pseudoparticles coated in SARS S failed to reliably produce luciferase readings
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above background (bald particle) levels (Figure 9). The second pseudotyping
system I employed was the VSV-based system (Fukushi et al 2008) that does
not rely on nuclear integration for gene expression. While VSV-based
pseudoparticles contain less SARS S protein than HIV-based pseudoparticles
(Figure 27), the particles do not face the same challenge of genome integration.
Therefore, reporter expression is relatively quick and not hampered by antiretroviral restriction factors. Accordingly, the VSV-based pseudoparticle system
was able to transduce Calu-3 cells with luciferase reporter gene above
background levels when coated with SARS S. Therefore, our future studies in
Calu-3 cells employed the VSV pseudoparticle transduction system.

Figure 8. Pseudotyping systems. Both pseudoparticles begin with transfection of
plasmids containing the genome and envelope protein (green) into producer
cells. The viruses are then synthesized and released into the media. The media
containing the pseudoparticles is then added to target cells. For HIV-based
pseudoparticles, the viral genome (red) must pass through the cytoplasm past
restriction factors and integrate into the host genome before the luciferase
reporter gene is expressed (yellow). Although VSV-based pseudoparticles
contain less spike protein produced, transcription of the reporter gene (purple)
occurs in the cytoplasm of the target cell.
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Figure 9. Transduction of SARS-S into various cell lines. HIV- or VSV- based
pseudoparticles coated in the indicated envelope glycoproteins were added to
indicated cell lines and allowed to bind for one hour at 37C. After one day for the
VSV-based pseudoparticle and two days for the HIV-based pseudoparticles, the
cells were lysed, and transduction was measured by a luciferase reporter.
Once I determined that Calu-3 cells contained levels of endogenous
TMPRSS2 that can potentially augment SARS-CoV entry, and that the virus
entry could be measured using VSV-based luciferase reporter pseudoparticles, I
set out to determine if the endogenous TMPRSS2 on Calu-3 cells was required
for optimal SARS S-mediated entry. To accomplish this, I stably transduced cells
with shRNAs targeted against TMPRSS2 (sh263 and sh10516) or a scrambled
control shRNA (shControl). We selected stable transduction as opposed to
transient transduction because the majority of Calu-3 cells do not contain the
exogenous DNA after transient transduction. The shRNAs were selected from an
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online database of gene-specific shRNAs created by The RNAi Consortium
(Institute 2012). After using pseudoparticle transduction and drug selection to
ensure that our cell population was somewhat homogenously expressing the
shRNA the cells were allowed to grow under selection without single cell cloning
because the cells did not propagate well in isolation. As seen in Figure 10,
endogenous levels of mature TMPRSS2 were reduced in the two targeted
shRNA cell lines. Using SARS S coated pseudoparticles, I transduced these cells
and found decreased S-mediated entry when TMPRSS2 levels were decreased
(Figure 10).

Figure 10. SARS-S transduction into Calu-3 TMPRSS2 Knockdown Cells. Calu-3
cells were transduced with particles expressing shRNAs directed against
TMPRSS2. Transduced cells were selected using puromycin. Left, reduction in
TMPRSS2 levels after indicated shRNA stably introduced into Calu-3 cells. Right,
transduction of VSV-based SARS-S coated pseudoparticles into indicated
knockdown cells normalized to entry into shCntl cells (average of three
independent experiments). Two-tailed t test ‡p=0.08, * p<0.05
It is worth noting that these cell lines did not maintain knockdown of
TMPRSS2 through multiple passages, and when TMPRSS2 returned to normal
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levels the entry of SARS also rebounded. Thus, TMPRSS2 was required for
optimal SARS S-mediated entry into Calu-3 cells.
To ensure that knockdown of TMPRSS2 was specific for the protease, I
attempted to add back shRNA resistant forms of TMPRSS2 to the Calu-3
knockdown cells. As the stable knockdown cells are under puromycin selection, I
created transducing particles containing shRNA resistant forms of TMPRSS2
with a GFP reporter. After transduction, a very low percentage of the cells were
GFP positive. However, there were sufficient cells to undergo fluorescence
activated cell sorting. After sorting, the GFP positive cells continued to grow for
approximately ten days. However, around two weeks after sorting, the cells
began to die. Assuming that the GFP positive cells overexpress TMPRSS2, this
finding supports previous attempts at creating cells stably expressing TMPRSS2
by our lab and others (Kawase et al 2012). It seems that artificially elevated
levels or abnormally regulated TMPRSS2 does not permit cell survival. Thus, this
control was unable to be completed. However, as two independent shRNA
knockdown cell lines both exhibited the same phenotype with respect to
TMPRSS2 and SARS S entry, it is supposed that the knockdown is TMPRSS2
specific.
As mentioned earlier, there are multiple proteases capable of cleaving
SARS S and enhancing entry (Bertram et al 2011, Glowacka et al 2011,
Matsuyama et al 2010, Matsuyama et al 2005, Shulla et al 2011, Simmons et al
2005). To determine the specific importance of TMPRSS2 compared to the
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known protease capable of cleaving SARS S, cathepsin L, I prevented
acidification of the endosome, a step necessary for activation of cathepsins.
Therefore bafilomycin treatment served as a surrogate for cathepsin L
inactivation. Compared to cells treated with bafilomycin alone, TMPRSS2
knockdown cells treated with bafilomycin exhibited a reduction in SARS Smediated entry (Figure 11). As the bafilomycin was suspended in DMSO, cells
were also treated with DMSO vehicle alone to assess the specific effects of
bafilomycin. SARS S entry was reduced in the TMPRSS2 knockdown cells
treated with DMSO compared to shControl cells treated with DMSO, as expected
based on previous studies in these knockdown cells. Therefore, the bafilomycin
is exerting an effect beyond that of vehicle alone.
Addition of trypsin to cells with bound SARS-CoV relieves the cathepsin L
cleavage requirement (Matsuyama et al 2005). To test if trypsin could also
bypass the requirement for TMPRSS2, I pretreated cells with bafilomycin, bound
virus onto the cells, and then added exogenous trypsin. Interestingly, trypsin
addition shows a trend toward restoring SARS S-mediated transduction into the
shControl cells but not the TMPRSS2 knockdown cells (Figure 12). Although
these experiments were not statistically significant, the results suggest that
cleavage of SARS S by TMPRSS2 differs from that of trypsin and cathepsin L.

Figure 11. SARS-S transduction into cells treated with bafilomycin. Calu-3 cells, control or knockdown, were
pretreated with 100nM bafilomycin (or DMSO control) for two hours at 37C. VSV-based with SARS-S coated
pseudoparticles were then added to cells and allowed to enter in the presence of bafilomycin for two additional
hours. Cells were then rinsed and complete media added. After 20 hours, cells were lysed and luciferase
measured. (data from three independent experiments). Two-tailed t-test * p<0.05 ** p<0.01
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Figure 12. Trypsin treatment on Calu-3 cells during SARS-S transduction. Calu-3 cells, control and knockdown,
were pretreated with 100nM bafilomycin prior to SARS-S coated pseudoparticle binding. After virus was bound at
4C for 30 minutes, indicated amounts of trypsin were added to the cells. Trypsin and unbound pseudoparticles were
removed and luciferase expression was measured to indicate transduction. Graph represents five independent
experiments.
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3.3 Apical release of proteins from Calu-3 cell surface
It is believed that TTSPs are cleaved from their zymogen on the cell
surface; therefore their mature form would only be present on the cell surface.
Some TTSPs are also produced as both transmembrane and soluble forms (Kim
et al 2001). It is possible that mature TMPRSS2 is released from the cell surface
and present in the extracellular mucus layer above respiratory epithelial cells
(also present on Calu-3 cells). TMPRSS2 in this layer could proteolytically prime
S while the virus was bound to ACE2. To determine whether cell surface proteins
were apically released from Calu-3 cells, washes from the apical surface of
differentiated Calu-3 cells were probed for TMPRSS2 and ACE2. While no
TMPRSS2 was released into the extracellular milieu, soluble ACE2 was found in
the washes (Figure 13). Our results support a previous finding that the ACE2
ectodomain can be shed from the cell surface (Glowacka et al 2010).
Additionally, infection with SARS-CoV was known to decrease levels of cellsurface ACE2 through stimulation of ADAM17 (Haga et al 2008).

Figure 13. Apical release of TMPRSS2 and ACE2 from Calu-3 cells. Left, apical
washes of the indicated control or knockdown Calu-3 cells were harvested and
probed for ACE2. Right, washes from above Calu-3 cells were probed for
TMPRSS2 and ACE2. Mono = submerged monolayer, ALI = differentiated airliquid interface
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3.4 TMPRSS2 and ACE2 complex in Calu-3 cells
As TMPRSS2 was not released apically, it was likely that ACE2 and
TMPRSS2 both interact with SARS S on the cell surface. The most logical way
for this to occur would be for TMPRSS2 and ACE2 to exist in the same
microdomain on the cell surface. Previously, I had examined transfected 293T
cells for localization of TMPRSS2 (detected by a FLAG tag) and ACE2 (detected
by SARS-RBD-Fc binding) (Shulla et al 2011). The two proteins appeared to
colocalize when both were present in sufficient quantities (Figure 14).
Experiments done by Ana Shulla looking at both ACE2 and TMPRSS2
transfected into cells were complicated by the fact that TMPRSS2 degrades
ACE2 (Shulla et al 2011). Therefore, both proteins coexist in detectable levels
only at specific ratios of ACE2:TMPRSS2. To determine if TMPRSS2 could
possibly be cleaving ACE2 in Calu-3 cells, I examined endogenous ACE2
expression. As seen in Figure 15, endogenous ACE2 existed in two different
species seen by western blot in Calu-3 cells. These two species correspond to
the fragments formed when ACE2 and TMPRSS2 are co-transfected together
(Figure 15). Although this data did not specifically implicate TMPRSS2 as the
ACE2 cleaving enzyme, it left the possibility open. However, when lysates of
TMPRSS2 knockdown cells were probed for ACE2, only the lower molecular
weight form was seen (Figure 16).
In addition to colocalizing with ACE2, TMPRSS2 was also coimmunoprecipitated with the ACE2 from transfected 293T cell lysates
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Figure 14. TMPRSS2 and ACE2 expression on transfected 293T cells. 293T
cells were transfected with the indicated ratios of ACE2- and TMPRSS2containing plasmids. After one day the cells were stained using anti-flag
(TMPRSS2) and SARS-RBD-Fc protein (ACE2).
(Shulla et al 2011). This biochemical assay suggests that ACE2 and TMPRSS2
were in a complex together. To determine if TMPRSS2 and ACE2 existed in a
complex in Calu-3 cells, I lysed cells under non-reducing conditions and probed
for both proteins. Interestingly, it was found that in both Calu-3 and 16HBEOcells, TMPRSS2 and ACE2 were detected at extremely high molecular weights
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(Figure 17). This finding suggests that TMPRSS2 is in a disulfide linked complex
with other proteins, including ACE2, possibly on the cell surface.

Figure 15. Endogenous ACE2 in Calu-3 cells. 293T cells were transfected with
increasing amounts of a plasmid containing TMPRSS2. Cell lysates of the
transfected 293T cells and Calu-3 cells were run on a western blot and probed
for TMPRSS2.

Figure 16. ACE2 in TMPRSS2 knockdown Calu-3 cells. TMPRSS2 knockdown
Calu-3 cells were lysed and immunoblotted under reducing conditions. The blot
was probed for ACE2, TMPRSS2, and beta-actin (loading control).
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Figure 17. Non-reducing gel of TMPRSS2 and ACE2 in Calu-3 cells. Calu-3 and
16HBEo- cells were lysed in the presence of N-ethylmaleimide and subjected to
SDS-PAGE. 293T cells transfected with the indicated plasmids served as
controls. The blot was probed with an antibody against TMPRSS2 then stripped
and reprobed with an antibody against endogenous ACE2 and β-actin (loading
control).
If ACE2 and TMPRSS2 were in a disulfide linked complex, they must
contain unpaired cysteines. While unpaired cysteines were documented for
ACE2 (Towler et al 2004), it was reported that the protease domain of TMPRSS2
contained nine cysteines, which were thought to form four intrasubunit and one
intersubunit disulfide bonds (Paoloni-Giacobino et al 1997). However, upon
closer examination I noticed that there were only eight cysteines in TMPRSS2,
and nineteen total in the ectoplasmic portion of TMPRSS2. By aligning most of
the human TTSPs, I confirmed that most of the cysteines were conserved.
However, TMPRSS2 contained a single unpaired cysteine at position 379 (Figure
18). All of TTSPs either contained paired cysteines at positions 379 and 447 or I
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lacking cysteines at both locations. Therefore, I hypothesized that this cysteine at
379 may be responsible for forming a complex with ACE2 and subsequently
explain why TMPRSS2 most potently augments SARS S-mediated entry (Shulla
et al 2011).
By mutating TMPRSS2 at positions 379 and 447, either to remove the
unpaired cysteine or provide the missing partner, I evaluated if this residue was
critical for the ACE2:TMPRSS2 interaction. Using immunoprecipitation, I were
able to pull down ACE2 in conjunction with both the wild type TMPRSS2 and the
C379L mutant (Figure 19). However, the T447C mutation TMPRSS2 failed to coimmunoprecipitate ACE2. This suggests that restoring the cysteine pair prevents
complex formation. However, it was perplexing that removal of the cysteine did
have the same result. As I thought that the disulfide linkage between ACE2 and
TMPRSS2 may be important for SARS-CoV entry, I measured S mediated entry
into cells expressing the mutant TMPRSS2s. Despite the biochemical data
suggesting a difference in the T447C mutant, all of the mutants augmented
SARS S entry to the same degree as wild type TMPRSS2 (Figure 20). This
finding led us to conclude that a disulfide-linked complex between ACE2 and
TMPRSS2 may not be necessary for SARS-CoV entry.
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Figure 18. Alignment of multiple TTSPs. Yellow indicates cysteines with an
identified partner for intrasubunit disulfide bonding. Blue indicates a cysteine that
forms an intersubunit disulfide bond with a cysteine not shown in this portion of
the alignment. Red indicates the cysteine at position 379 of TMPRSS2 along with
the threonine at position 447. Green indicates the TTSPs that do not contain
cysteines at the positions corresponding to 379 and 447 of TMPRSS2.
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Figure 19. Immunoprecipitation of mutant TMPRSS2 and ACE2. Plasmids
containing the indicated TMPRSS2-Flag constructs were cotransfected with
ACE2-C9 in 293T cells. Cells transfected with empty vector serve as negative
control. After binding anti-Flag antibody to protein G beads, cell lysates were
captured. Following extensive washed, captured proteins were eluted in reducing
buffer and subjected to SDS-PAGE. Blot was probed with the 1D4 antibody (antiC9) then stripped and reprobed using anti-Flag.

Figure 20. SARS-S Transduction into cells expressing mutant TMPRSS2. 293T
cells were transfected with plasmids containing the indicated TMPRSS2
constructs (wt = wild type) or empty vector (pCAGGS). HIV-based
pseudoparticles coated with SARS-S and VSV-G were added to cells for one
hour. After two days, cells werelysed and transduction measured by luciferase
expression.
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3.5 Localization of endogenous TMPRSS2 on the Calu-3 cell surface
While I had shown that endogenous ACE2 and endogenous TMPRSS2
may be in a complex somewhere within Calu-3 cells, I wanted to look for the
localization of the proteins on the cell surface. The proteins could be in complex
within the cell but not on the cell surface. No one has reported the cell surface
localization of endogenous TMPRSS2 by immunofluorescence. To confirm that
our antibody was detecting TMPRSS2 and not being caught nonspecifically in
the apical mucus layer, I probed unpermeablized Calu-3 cells for TMPRSS2. In
addition to using a secondary antibody against the TMPRSS2 primary antibody, I
also used an unpaired secondary antibody of a different wavelength to show
background antibody binding. Using a line profile analysis, I determined that the
ratio of TMPRSS2 specific staining to the background staining was much higher
than the ratio of the two secondary antibodies added in absence of a primary
(Figure 21).
This suggests that the TMPRSS2 primary antibody gave a signal above
background antibody binding. To determine if the TMPRSS2 antibody was
specifically detecting TMPRSS2, I used two different species of primary
antibodies on the same cells. In Figure 22, I observed that both TMPRSS2
antibodies recognized the same area on the surface of Calu-3 cells. This
confirmed that the primary antibodies were specific for TMPRSS2 staining.
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Figure 21. Line Profile analysis of TMPRSS2 staining on Calu-3 cells. Calu-3
cells stained for ACE2 and TMPRSS2 or no primary antibodies were imaged and
analyzed using a line profile. Peaks of non-specific staining (background, white
peaks) were compared to TMPRSS2 staining (turquoise peaks).
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Figure 22. Dual TMPRSS2 staining on Calu-3 cells. Calu-3 cells were probed
with two TMPRSS2 antibodies (one mouse and one rabbit). Secondary
antibodies with different fluorophores were used to distinguish the staining of
each antibody.
While staining the Calu-3 cells, I noticed that TMPRSS2 had a very
distinct staining pattern. Although the ACE2 staining was punctate, it fairly
uniformly coated the surface of positive cells. On the other hand, TMPRSS2
localized to a discrete region of the cell surface. As TMPRSS2 appeared to be
confined to a specific membrane microdomain, I attempted to characterize
exactly which type of microdomain it is located in. The plasma membrane of cells
is known to have areas distinct from each other based on their composition.
Mostnotably, cells contain lipid rafts containing higher amounts of cholesterol
than the rest of the membrane (Simons & Gerl 2010). Additionally, there are
other areas on the cell surface indicated by numerous cell surface molecules.
One such group of markers are tetraspanins. These form distinct tetraspanin
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enriched microdomains (TEMs) (Levy & Shoham 2005). Because tetraspanins
are thought to influence protease activity and based on the staining pattern of
TMPRSS2, I hypothesized that TMPRSS2 may preferentially localize to one of
these membrane TEMs. To determine if TMPRSS2 was localized within a TEM, I
stained Calu-3 cells for different tetraspanins in conjunction with TMPRSS2. I
discovered that TMPRSS2 and CD63 localized to similar regions, forming a ringlike pattern on the cell surface (Figure 23). To confirm that this association was
specific for CD63, we performed a double-blind experiment with three different
tetraspanins where one person performed the imaging and another person
completed the analysis. CD63 association with TMPRSS2 was statistically more
likely than the other tetraspanins (Figure 24). Thus, TMPRSS2 appeared to be in
a CD63 TEM on the surface of Calu-3 cells.
3.6 Effect of SARS S-mediated binding on TMPRSS2 localization
After discovering that TMPRSS2 and ACE2 were located in different
membrane microdomains on the surface of Calu-3 cells, I sought to determine
how the two proteins both impact SARS S during viral entry. To biochemically
isolate the cell surface TMPRSS2, I used a biotinylation assay for Calu-3 cells
(Figure 25). The biotinylation reagent we selected cannot penetrate the cell
membrane, thus labeling only proteins with extracellular portions. This allowed us
to focus specifically on the cell surface localized TMPRSS2, the proportion of the
protein population that can interact with entering SARS-CoV particles.

Figure 23. CD63 staining on Calu-3 cells. Calu-3 cells were stained for CD63 (red), TMPRSS2 (green), and ACE2
(blue). Nuclei are in gray.
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Figure 24. Comparison of tetraspanins in TMPRSS2 regions. Assessment of tetraspanin staining near TMPRSS2
regions. Submerged monolayers of Calu-3 cells were stained for TMPRSS2 (green) and one of three tetraspanins
(red). Imaging and analysis was done by separate people in a double-blind fashion. The graph on right depicts the
ratings of various regions for each of the tetraspanins. *p=<0.005 by two tailed t-test
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Figure 25. Biotin Pull-down of cell surface TMPRSS2. Calu-3 cells and 293T cells
transfected with TMPRSS2 were biotinlyated, lysed, and cell surface biotinylated
proteins were pulled down by strepavidin magnetic beads. The original lysate, as
well as the bound and unbound portions of the pull-down were subjected to
western blotting and probed for TMPRSS2.
While it was known that ACE2 was located in lipid rafts (Lu et al 2008), no
studies had examined the localization of endogenous TMPRSS2 on the cell
surface. To determine this, we employed detergent resistant membrane flotation
to isolate the lipid raft portions of the cell membrane. Confirming the previous
reports, ACE2 did appear to be within lipid rafts by this assay (arrow in Figure
26). However, TMPRSS2 was not located in lipid rafts, despite its association
with TEMs (Figure 26). We hypothesized that SARS-CoV binding to ACE2 may
induce TMPRSS2 relocalization, bringing it into lipid rafts and therefore closer to
the ACE2:S complex. We tested this by binding HIV-based pseudoparticles to
transfected 293T cells as they contain a higher amount of SARS S than VSV-
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based pseudoparticles (Figure 27). For this experiment, we used 293T cells as
they can produce higher levels of TMPRSS2 and ACE2 than Calu-3 cells,
making detection easier. After binding, we shifted the cells to a higher
temperature, permitting lateral diffusion throughout the membrane. After sixty
minutes, we discovered some TMPRSS2 in the lipid raft portions of the cell
membrane (Figure 28). I repeated this experiment in Calu-3 cells with some
success (Figure 29). This experiment indicates that SARS-CoV binding to the
host cell induces relocalization of TMPRSS2 to lipid rafts, possibly nearer to the
receptor.

Figure 26. DRM flotation of TMPRSS2. 293T cells transfected with TMPRSS2
and Calu-3 wild type cells were biotinylated, lysed, and floated through a
discontinuous sucrose gradient by ultracentrifugation. Fractions of the gradient
were harvested and samples were taken (lysate) before addition of streptavidin
beads. After incubation with streptavidin beads, the bound proteins were eluted
(bound). Both the bound and lysate samples were run on western blot and
probed for TMPRSS2 (and ACE2 for the Calu-3 cells).
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Figure 27. Comparison of SARS-S incorporation into HIV or VSV-based
pseudoparticles. Pseudoparticles with either an HIV or VSV background were
created in parallel. Various dilution of the plasmid containing SARS-S were
transfected into the producer cells. Particles were harvested and concentrated by
ultracentrifugation. Pelleted particles were examined by western blot and SARSS was detected

Figure 28. Detergent Resistant Membrane Floatation on 293T cells. HIV-based
pseudoparticles were added to 293T cells cotransfected with TMPRSS2 and
ACE2. The cells were then biotinylated, lysed, and floated through a
discontinuous sucrose gradient by ultracentrifugation. Fractions of the gradient
were harvested and samples were taken (lysate) before addition of streptavidin
beads. After incubation with streptavidin beads, the bound proteins were eluted
(bound). Both the bound and lysate samples were run on western blot and
probed for TMPRSS2 (Flag-tag).

66

Figure 29. DRM flotation of TMPRSS2 after SARS-S particle addition. HIV-based
pseudoparticles were added to Calu-3 (Bald serves as negative control). The
cells were then biotinylated, lysed, and floated through a discontinuous sucrose
gradient by ultracentrifugation. Fractions of the gradient were harvested and
samples were taken (lysate) before addition of streptavidin beads. After
incubation with streptavidin beads, the bound proteins were eluted (bound). Both
the bound and lysate samples were run on western blot and probed for
TMPRSS2.
3.7 NL63-CoV plaque formations on CaCo2 cells

Figure 30. NL63 replication in CaCo2 cells. NL63 stains GER and IA were
plaqued on CaCo2 cells and subjected to RT-PCR in parallel.
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While the majority of our research focused on SARS-CoV entry, I also
explored ways to study other HCoVs such as NL63-CoV. As mentioned earlier,
research on HCoVs other than SARS-CoV is difficult because their growth is
extremely fastidious in cell culture systems. Additionally, they do not usually
cause syncytial development or cytopathic effects in cell monolayers, a typical
measure of viral growth. However, a paper was recently published that reported
NL63-CoV induced plaques, when grown on a human intestinal cell lines, CaCo2 (Herzog et al 2008). To test two of our NL63-CoV viral stocks for plaque
development, I performed a plaque assay in parallel with reverse transcription
polymerase chain reaction (RT-PCR) detection of viral RNAs. In both of our
NL63-CoVs, I were able to detect viral infection by RT-PCR at dilutions lower
than those that had plaques (Figure 30). However, the NL63-CoV GER virus was
able to develop plaques at a higher dilution that the NL63-CoV IA virus.
Therefore, the two different NL63-CoVs in our lab appeared to differ in their
ability to form plaques. To determine if this difference was due to mutations in S,
I sequenced a cDNA library containing the entire S of each NL63-CoV. However,
no differences were found in the sequence between the GER and IA virus (data
not shown). Therefore, it is possible that there are factors outside of S influencing
plaque formation.
In addition to having two different NL63-CoVs, I also had CaCo-2 cell lines
from two different labs. When I performed plaque assays on these two cell lines
with both of our NL63-CoVs, I noticed that, in addition to NL63-CoV GER forming
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more plaques in general, NL63-CoVs produced in the CaCo-2 tc7 cells formed
plaques while the NL63-CoVs produced on the CaCo-2 GER cells were unable to
form plaques (Table 3). This indicated that the NL63-CoV producer cells
influenced the ability to form plaques. Additionally, the NL63-CoV IA was unable
to form plaques on the CaCo-2 GERs while it could produce minimal plaques on
CaCo-2 tc7 cells. From these experiments, I concluded that the two cell lines,
GER and tc7, contained different factors that influenced NL63-CoV plaque
formation.
As the two CaCo-2 cell lines came from the same source, they mostly
likely diverged only slightly throughout passage in culture. However, the NL63CoV phenotype varied greatly between the two cell lines. Therefore I
hypothesized that I could compare the two cell lines and identify the important
factor(s) for NL63-CoV syncytial growth more readily on these cells given their
minimal differences. To undertake experiments exploring growth of NL63-CoV on
these cells lines, I needed a virus with a reporter expressed after entry that also
contained the S protein of NL63-CoV. I decided that only the ectoplasmic portion
of S would be important for entry because the S1 domain, containing the RBD, is
entirely ectoplasmic. As I do not have an NL63-CoV with a reporter gene, I
cloned the ectodomain of NL63-CoV S into an existing recombinant MHV-CoV.
By retaining the endodomain of MHV-CoV S, it I assumed that is would be able
to assembly normally with the other MHV structural proteins based on previously
constructed recombinant CoVs (Kuo et al 2000). To confirm that our chimeric S
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protein could be expressed, I cloned out the chimeric S from the recombinant
virus and placed it in an expression plasmid with a c9 tag. After lysing cells
transfected with this plasmid, I confirmed chimeric S expression using western
blot (Figure 31). The chimeric S could be produced and detected at its expected
size.
Table 3. Comparison of plaques formed by the two strains of NL63 on different
strains of CaCo2 cells.
Producers

Virus

CaCo2 GER

CaCo2 tc7

Indicators

GER

tc7

GER

tc7

NL63-GER

No
plaques

No
plaques

Diffuse plaques
to 10-4

Clear plaques
to 10-4

NL63-IA

No
plaques

No
plaques

No plaques

Clear plaques
to 10-1

Figure 31. Creation of chimeric NL63/MHV Spike protein. The ectoplasmic
portion of NL63 S was inserted into a plasmid encoding recombinant MHV virus,
then removed and placed in a plasmid containing a C9 epitope tag. 293T cells
transfected with the plasmid were evaluated for protein expression by western
blot.
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Figure 32. Transduction using chimeric spike protein. Left, 293T cells were
transfected with HIV core (encoding a luciferase reporter gene) alone (as a
negative control) or along with the indicated S plasmids: VSV-G (positive
control), MHV-S, NL63-S, or the chimeric NL63Secto-MHVSendo.
Pseudoparticle producer cells were incubated for two days at 32C after which
time pseudoparticles were collected from the supernatants, pelleted at 200Kxg
for 30 minutes, and subjected to western immunoblotting. The chimeric S
construct produced a protein, which incorporated into pseudoparticles. This blot
was probed for gag and the c9 tags of the chimeric and NL63-S proteins.
Despite a protein being produced, I needed to confirm that the chimeric
spike was capable of mediated membrane fusion. To assess membrane fusion, I
used the HIV-based pseudotype system. After creating particles containing the
chimeric spike (Figure 32), I attempted to transduce cells expressing ACE2.
While the protein was expressed and incorporated into pseudoparticles, it did not
transduce cells expressing ACE2 above background levels (Figure 32).
In addition to checking for chimeric S incorporation into our HIV-based
pseudoparticles, I also looked for incorporation of the chimeric S into MHV-CoV
virus like particles (VLPs). VLPs are created by expressing the viral structural
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proteins within the same cells. These structural proteins assemble into a noninfectious particle, allowing me to manipulate the components of virus assembly.
By expressing the structural proteins of MHV-CoV, non-infectious virions are
formed and released in the supernatant as mimic of viral release. Again, the
chimeric S protein was expressed in transfected 293T cells, along with the other
structural proteins. However, the chimeric S was not incorporated into VLPs
released into the supernatant (Figure 33). Therefore, the chimeric S was nonfusogenic and did not incorporate into MHV-CoV virions. As our experimental
system to investigate NL63 S-based entry into the two Calu-3 cell types failed
during development, I was no longer able to pursue this line of experimentation.
Alternative methods of exploring the host factors important for NL63-CoV entry
are discussed in the next chapter.

Figure 33. Incorporation of chimeric spike into MHV VLPs. Plasmids containing
the indicated S constructs were transfected alongside the other structural
proteins of MHV. VLPs produced in the cells along with cell lysates were
evaluated by western blotting for the MHV-N, MHV-M and the c9 tag on S.
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3.8 Cytokine release in response to HCoV S-mediated entry
Although most host factors studied in CoV entry are exploited by the virus
to create a portal for delivery of the genome, the host cell also contains proteins
that serve to stimulate the immune system and provide the host a warning of the
invader’s presence. These invader-sensing host factors typically do not
recognize viruses during the entry stage. However, there are cell surface and
endosomal sensors that are triggered during bacterial invasion. Therefore, I
hypothesized that a host factor may be sensing S-binding and entry of the virus.
Previous work had indicated that the SARS-CoV entry process itself may trigger
an immune response (Chang et al 2004, Dosch et al 2009, Miura et al 2007,
Wang et al 2007, Yoshikawa et al 2009). Because both SARS-CoV and NL63CoV use the same host cellular receptor, we hypothesized that perhaps
differences in the severity of the infectious diseases could be traced back to their
S:ACE2 interaction. It has been previously discovered that despite binding similar
hotspots, NL63-S has much less affinity for ACE2 than SARS-S (Wu et al 2009).
To explore this, I created soluble S mimics containing portions of S. Either the
entire S1 subunit or just the RBD portions were cloned in a plasmid expressing
the human immunoglobulin type G fragment crystallizable (Fc) region. This
allowed the protein to be created in 293-EBNA cells and exported intact into the
supernatant for collection. To assess the amount of protein harvested, I
electrophoresed proteins under non-reducing conditions and subjected them to
silver staining (Figure 34).

73

Figure 34. Creation of Fc proteins. Plasmids containing Fc fusion proteins were
transfected into 293-EBNA cells. Proteins in the supernatants were harvested
and purified over sepharose columns. Protein concentration was determined by
comparing the proteins to known concentrations of NCEACAM-Fc on a silver
stained western blot.
Despite being capable of producing, concentrating, and purifying these
CoV-Fc proteins, I needed to assess their functionality. One method to assess
their proper folding and functionality was to use them to capture ACE2 protein by
immunoprecipitation. It is known from other studies that SARS-CoV S1 and RBD
have higher affinities for ACE2 than either NL63-CoV region (Wu et al 2009).
Therefore, it was not surprising that both SARS-CoV S proteins bound ACE2 the
highest amounts of ACE2 in our assay (Figure 35). Despite the lower affinities of
the NL63-CoV proteins, there was some detectable ACE2 binding indicating that
they were most likely functional. To confirm all the protein’s functionality in an
additional assay, I blocked the transduction of SARS S containing HIV-based
pseudoparticles from entering 293T cells expressing ACE2 by pretreating the
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cells with the soluble proteins. In Figure 36, I observed that both SARS S
constructs successfully blocked SARS S mediated transduction. Not surprisingly
given its low affinity for ACE2, NL63 S1-Fc did not block SARS S transduction.
However, I were unable to fully test the efficacy of NL63 RBD-Fc due to low
concentrations of the protein. Overall, these assays confirmed that our proteins
were functional and suitable for use in future studies.

Figure 35. Immunoprecipitation of ACE2 using Fc proteins. ACE2 in transfected
293T cell lysates was precipitated using Fc fusion proteins. Untransfected 293T
cells served as a negative control (-).
While our Fc constructs were useful in mimic the receptor binding function
of the S1 subunit, they neglected to account for any effects of membrane fusion
due to the S2 subunit. To explore the importance of fusion on immune signaling,
we created full S constructs that were incapable of mediated membrane fusion
by mutating phenylalanines at residues 805 and 878 to alanines in SARS and
NL63, respectively (Madu et al 2009). As seen in Figure 37, the mutant forms of
S incorporated as well as the wild type S for both SARS and NL63. However, the
mutants were unable to mediate membrane fusion as measured by HIV-based
pseudoparticle transduction into 293T cells expressing ACE2. Therefore, I had
constructs in place to measure immune responses to all functional aspects of S.
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As I were interested on immune signaling in response to HCoV entry, I
assessed release of two cytokines important for the early immune response from
cells to which our Fc proteins were added. The cytokines were selected were
interleukins -8 and -6 (IL-8 and IL-6). These proinflammatory cytokines were
chosen because multiple studies of SARS-CoV infection found them to be
elevated (Chan et al 2006, Frieman et al 2008). For these studies, I used
differentiated Calu-3 cells that form tight junctions, allowing us to assess if
cytokine release was apical or basolateral. In preliminary work, I discovered that
SARS S1-Fc stimulated release of IL-6 apically and IL-8 both apically and
basolaterally (Figure 36). Unfortunately, I was unable to continue these studies
with the remaining S mimics I had created due to technical limitations. Methods
to improve the experiments are covered in the discussion section of this
document.
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Figure 36. Blockade of SARS-S transduction by Fc proteins. Fc fusion proteins at
the indicated concentrations were added to 293T cells expressing ACE2 prior to
pseudoparticle addition. Luciferase expression (RLU) indicated entry of each
pseudoparticle into the cells.
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Figure 37. Creation of fusion mutant Spike proteins. Left, 293T cells were
transfected with both HIV core and the indicated S plasmids. Pseudoparticle
producer cells were incubated for two days at 32C after which time
pseudoparticles were collected from the supernatants, pelleted at 200Kxg for 30
minutes, and subjected to western immunoblotting. All S constructs incorporated
similarly as indicated by immunoblot signal ratios of S to HIV gag proteins. Right,
Unpelleted pseudoparticles were applied to 293 cells stably expressing ACE2.
After 48 hours luciferase expressions were measured using Promega Luciferase
Assay System. Fusion activity, measured by transduction capability, is reported
as percent transduction of the mutant compared to wild type.
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Figure 38. Cytokine release from Calu-3 cells. NL63 S1-Fc, SARS S1-Fc, and
negative control NCEACAM-Fc proteins were apically applied to polarized Calu-3
cells at the indicated concentrations. After six hours, cytokines from apical
washes (top) were measured by ELISA along with cytokines in the basolateral
media (bottom). All cytokine values are reported as the total nanograms released
from each parallel culture.

CHAPTER FOUR
DISCUSSION
4.1 Proteases and HCoV S cleavage
Viruses depend on transmission between hosts for their lifecycle. These
transmission events often occur over great distances, relative to virion size, and
through many environments. For example, most HCoVs are produced in the
respiratory tract, travel with mucus toward the nasal cavities before being
expelled. Once outside the human body, the virus encounters an entirely different
environment, one that is much colder and drier than its original site of
propagation (Chan et al 2011). After traversing the outside world, the virus may
enter a new host. However, viral replication depends on the virion entering the
appropriate cell type. This brings up a central question in virology- how does a
virion recognize the ideal target cell and enter that cell type?
Many enveloped viruses have class I fusion proteins capable of
recognizing and fusing with host target cells (Bullough et al 1994, Chan et al
1997, Malashkevich et al 1999, Weissenhorn et al 1997, Wilson et al 1981). The
first interactions occur through receptors, or co-receptors, which attach the virus
to the host cell. In addition to binding the virion to the cell, this receptor
interaction also triggers the refolding process, along with other molecular triggers
of glycoprotein refolding. The receptor binding portion of the envelope
79
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glycoprotein dissociates, exposing a fusion peptide that can insert into the host
cell membrane. The heptad repeat domains then are able to fold upon
themselves, bringing the viral and cellular membranes closer until they fuse.
For this refolding process to occur, most glycoproteins require proteolytic
cleavage to allow for fusion peptide exposure after receptor binding and other
triggers (Harrison 2008). Some viral glycoproteins are cleaved during virus
production (Bullough et al 1994, Wilson et al 1981), while others are cleaved
after transmission to their new host (Malashkevich et al 1999, Matsuyama et al
2005, Simmons et al 2005). For SARS-CoV S, research suggests that cleavage
that occurs prior to receptor binding actually inactivates the fusion machinery
(Matsuyama et al 2005). Thus, the timing of proteolytic cleavage in relation to
receptor binding can be critical. Also, proteases recognize different consensus
sequences and their cleavage can have varying effects on the glycoprotein.
Multiple host proteases are capable of cleaving, and thus activating, CoV
S proteins, but most studies have focused on a single protease using transient
overexpression or pharmacologic manipulation (Glowacka et al 2011,
Matsuyama et al 2010, Matsuyama et al 2005, Simmons et al 2005). This
dissertation describes a different approach, reducing the levels of an
endogenous protease along with pharmacologic manipulation. The results
demonstrate that different proteases may affect SARS S-mediated entry in
unique ways.
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4.1.1 TMPRSS2
While previous work has explored the effects of overexpressed TMPRSS2
on SARS-CoV entry (Glowacka et al 2011, Matsuyama et al 2010, Shulla et al
2011), none had examined the functional role of endogenous TMPRSS2
respiratory tract cells, although recent work does show that endogenous
TMPRSS2 is present on the human respiratory tract (Bertram et al 2012). Our
work demonstrated that by reducing the levels of endogenous TMPRSS2 in a
respiratory epithelial cell line, Calu-3, SARS S-mediated entry was also reduced.
Calu-3 cells are appropriate mimics of the respiratory tract that have been used
as models of the respiratory epithelium in SARS-CoV infection (Tseng et al
2005). While these cells become differentiated on an air-liquid interface, the
submerged monolayer of Calu-3s also reflects the respiratory epithelium. Indeed,
I found no difference in the endogenous levels of TMPRSS2 protein in the
submerged monolayer and differentiated cultures. Additionally, mRNA levels of
endogenous TMPRSS2 are similar in submerged Calu-3 cells and human lung
tissue (Kawase et al 2012). Therefore, TMPRSS2 appears to be necessary for
optimal SARS-CoV entry into the respiratory tract.
The next logical step in this investigation is to determine whether
TMPRSS2 reductions diminish SARS-CoV entry. One group has begun
investigating protease inhibitors currently in clinical use for effects on SARS-CoV.
One agent, camostat, was able to decrease SARS-CoV replication in Calu-3 cells
(Kawase et al 2012). In addition to broad-range protease inhibitors, there are
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other possible mechanisms to decrease TMPRSS2 activity in vivo. As there are
no known physiological roles of TMPRSS2, specific targeting of this protease
may have limited side effects. One method would act specifically against
TMPRSS2 by delivering an oligonucleotide directed against the TMPRSS2
mRNA to reduce the protein levels. This strategy has been used in cell culture to
reduce influenza replication, as TMPRSS2 is known to cleave influenza HA
(Bottcher-Friebertshauser et al 2011). The second method to decrease
TMPRSS2 in the respiratory epithelium would be a more indirect approach.
Recently, it was reported that increased levels of ozone might lead to an
imbalance between protease and antiproteases. By providing cells with
antioxidants, researchers were able to increase the levels of antiproteases, thus
shifting the balance away from pro-viral proteolysis (Kesic et al 2012). This
therapy would be advantageous because it does not necessarily rely on
commercially developed pharmaceuticals. In the case of another pandemic
HCoV, large populations could boost their protection using commonly available
foods such as berries and beans. Of course, the efficacy of this method is yet to
be tested in humans. However, the other therapies may only be valuable for
short-term preventative treatment in high-risk population such as health care
workers. It is worth noting that all three of these methods would be broad-range
antiviral candidates because wide ranges of viruses depend on the proteases.
Thus, these pharmaceutical agents would not only be medically but also
commercially beneficial to develop.
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While the data presented in this paper, as well as others, suggest that
TMPRSS2 plays an important role in SARS-CoV entry; the possibility remains
that other TTSPs may also be relevant SARS-CoV entry factors. Given the fact
that HAT and TMPRSS2 cleave SARS S in different ways (Bertram et al 2011), it
is possible that they both may play a role in enhancing SARS-CoV entry.
Additionally, many of the other TTSPs such as TMPRSS3, TMPRSS4,
TMPRSS6, and Hepsin have been explored alone in over-expression systems
(Bertram et al 2011, Glowacka et al 2011). By exploring combinations of these
proteases, or the endogenous proteins in human tissues, a better understanding
of S cleavage will emerge.
4.1.2 Cathepsins and Extracellular Proteases
While TMPRSS2 appears to play a significant role in SARS-CoV entry,
other proteases also cleave SARS S during the entry process (Matsuyama et al
2005, Simmons et al 2005). An open question in coronavirology is the role of
each of these proteases. Some results suggest that multiple proteases have
redundant functions on SARS-CoV entry (Belouzard et al 2009). Introducing a
cleavage site into CoVs that allows S proteolysis during virus production
bypassed the requirement for endosomal cathepsins (Belouzard et al 2009,
Watanabe et al 2008). This experiment indicated that SARS S merely required
cleavage, regardless of the exact protease. However, it has been proposed that
CoV S undergoes cleavages at multiple sites (Belouzard et al 2009). One
protease cleaves closer to the receptor-binding domain, freeing it from the rest of
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S after receptor binding while a second protease cleaves N-terminal to the fusion
peptide, likely allowing the FP to intercalate into the cellular membrane (Bosch et
al 2008). Therefore, the different proteases might have complimentary roles in
which they each impact an important step in S refolding during virus entry
(Belouzard et al 2009).
The results presented in this dissertation suggest the view that the
different proteases are not functionally redundant, but rather multiple proteases
are required for optimal SARS-CoV entry is possible. When bafilomycin was
added to TMPRSS2 knockdown cells, SARS S-mediated entry was reduced
compared to TMPRSS2 knockdown cells alone. While this suggests that both
cathepsins and TMPRSS2 are required for optimal SARS-CoV entry, it must be
considered that bafilomycin can have effects beyond cathepsin inhibition (Bayer
et al 1998). One such effect is the alteration of endocytic transport. Therefore, it
remains a possibility that this experiment indicates that SARS-CoV requires
TMPRSS2 cleavage along with an endosomal route of entry, regardless of the
activation status of cathepsins. Further studies into this question could be
undertaken using specific cathepsin inhibitors. For example, cathepsin L is
known to be the important protease for SARS S cleavage. Therefore, TMPRSS2
knockdown cells could be treated with EST, a cathepsin L inhibitor, to see if the
bafilomycin induced effects are specifically due to cathepsin L inhibition or
alternatively a pleiotropic effect of bafilomycin. I expect that the experiment will
show similar results to our bafilomycin experiment as it was recently shown that
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both bafilomycin and EST resulting in similar diminution of SARS-CoV entry
(Kawase et al 2012).
An additional line of inquiry into the effect of exogenous proteases, such
as trypsin, on SARS-CoV entry relative to TMPRSS2 could also yield interesting
results. One experiment aimed at addressing this issue was attempted by the
addition of trypsin to cells during pseudovirus entry. As trypsin treatment was
shown to alleviate the need for cathepsins during entry (Matsuyama et al 2005),
it was supposed that trypsin could also replace TMPRSS2 proteolysis. However,
trypsin did not appear to “rescue” the decreased SARS S-mediated entry into
TMPRSS2 knockdown or control cells. While not statistically significant, this
result suggests that trypsin and cathepsin cleave SARS S in a different manner
than TMPRSS2. Taken together, the results of our studies indicate that
TMPRSS2 and the other proteases are not functionally redundant during SARSCoV entry.
4.2 ACE2 and TMPRSS2 Interaction
As SARS-CoV interacts with the receptor, ACE2, and the protease
TMPRSS2 during entry (Li et al 2003), it would be logical that they are located
near each other on the cell surface. However, immunofluorescence data
demonstrated that ACE2 and TMPRSS2 reside in different compartments on the
cell surface. Because of their disparate locations, it is intriguing that they both
play such a profound role on SARS-CoV entry. One must remember the fluid
nature of the plasma membrane when considering this question. While there are
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certain microdomains on the cell surface, these “domains” are under constant
flux (Simons & Gerl 2010). They form and break apart continually. Thus, while a
protein may appear to be primarily located in a certain microdomain by
immunofluorescence, it is likely that there is some proportion of the protein
moving through the membrane at lower concentrations, below the limit of
detection. This section will explore how two proteins that are not in the same
membrane microdomains influence SARS-CoV entry.
4.2.1 Apical release of ACE2
One possible way that ACE2 and TMPRSS2 could both impact SARSCoV as it approaches and binds the cellular membrane would be if one of the
proteins were released into the apical extracellular mucus layer. By western blot,
it appears that ACE2 is apically released from Calu-3 cells, similar to reports of
ACE2 ectodomain shedding from the human respiratory tract. This release of
ACE2 could influence SARS-CoV pathogenesis in multiple, and somewhat
opposing way. The most likely result of ACE2 release is a decreased infectivity of
SARS-CoV. The decrease would be due to SARS S binding to ACE2, triggering
a premature conformational change and effectively neutralizing the virion.
Soluble ACE2 acting to neutralize incoming pseudoparticles containing SARS S
has been previously demonstrated (Fukushi et al 2008).
Alternatively, reports from MHV-CoV indicate that soluble receptor added
to cells could potentiate entry into cells not expressing the receptor (Taguchi &
Matsuyama 2002). Cells infected with MHV-JHM were overlaid onto cells that did
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not express the receptor. As expected, the cells without a receptor were unable
to become infected. However, when soluble receptor was added during overlay,
the virus was able to enter the receptor-less cells (Taguchi & Matsuyama 2002).
Another study demonstrated that MHV-CoV was capable of binding to liposomes
in the presence of soluble receptor (Matsuyama & Taguchi 2009). Thus, there is
a possibility that soluble CoV receptors actually enhance CoV entry. Although
unlikely, it is possible that soluble ACE2 near the apical cellular membrane could
stimulate binding to the host cell and alter S confirmation enough to expose
TMPRSS2 cleavage sites and thus increase entry. Additionally, ACE2 is thought
to play a protective role against lung injury (Imai et al 2005, Kuba et al 2005).
Thus, decreasing levels of ACE2 on the cell surface could make the lung more
vulnerable to SARS-CoV infection and therefore increase pathogenesis.
4.2.2 ACE2 and TMPRSS2 in complex
Our original hypothesis was that a TMPRSS2:ACE2 complex assisted in
viral entry at the cell membrane, but given that the proteins are not near each
other on the cell surface, it is possible that ACE2 and TMPRSS2 interact in an
intracellular compartment. On a whole cell level, ACE2 appeared to be cleaved
by TMPRSS2 in a 293T overexpression system (Shulla et al 2011). Perhaps
TMPRSS2 interacts with ACE2 during protein production and transport to the cell
surface. TMPRSS2 may encounter ACE2 and cleave it prior to reaching the
plasma membrane. This proteolyzed ACE2 may serve as an improved receptor
for SARS-CoV, as previous studies found that while TMPRSS2 cleaved ACE2,
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SARS entry increased (Shulla et al 2011). Thus the question becomes, what is
the more important target of TMPRSS2 for optimal SARS-CoV entry? While I
have assumed that TMPRSS2 enhanced SARS-CoV entry by direct S cleavage,
it might also act by altering the structure of ACE2 such that S binding is
enhanced. It would be interesting if one could manipulate levels of ACE2 and
TMPRSS2 independently to tease out the role of each in relation to SARS-CoV.
Likely, there is an ideal balance of ACE2 and TMPRSS2 levels on the cell
surface for optimal SARS-CoV entry.
4.2.3 Immunofluorescence of cell surface proteins
Although TMPRSS2 and ACE2 both affect SARS-CoV during entry, they
are not located in the same region on the surface of Calu-3 cells. This is
surprising given that our previous study looking at TMPRSS2 and ACE2 on the
surface of 293T cells overexpressing both proteins found that they had similar
localization patterns (Shulla et al 2011). However, this finding was most likely an
artifact and our experiments done on Calu-3 cells examining endogenous
proteins are probably more representative of the true expression patterns in vivo.
During our examination of TMPRSS2 on the Calu-3 cell surface, I noticed
that it appeared in a distinct ring-shaped pattern. The pattern was similar to other
reported cell surface structures such as some tetraspanin-enriched
microdomains (TEMs) (Garcia et al 2008). TEMS, as their name suggests, are
portions of the plasma membrane specifically enriched in certain tetraspanins
(Levy & Shoham 2005). Indeed, I found that TMPRSS2 specifically colocalized
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with the tetraspanin CD63, a tetraspanin found on the cell surface TEMS and
within endosomes (Pols & Klumperman 2009). There are multiple different
tetraspanins that are located in different TEMs. These TEMs are often platforms
for cellular activity as the tetraspanins associate with other proteins, and in turn
those can connect to tertiary partners creating a web of protein-protein
interactions (Levy & Shoham 2005). Recently, researchers have noted a possible
role for TEMs in protease activity (Yanez-Mo et al 2011). In the case of
TMPRSS2, one would imagine that the protease activity would need to be under
tight regulation to prevent unrestricted degradation of other cell surface proteins.
Therefore, confining TMPRSS2 to a specific TEM may be a cellular mechanism
for controlling protease activity.
Recent evidence suggests that tetraspanins and TEMs may play a role in
viral entry. Most notably, the Hepatitis C virus has been shown to use the
tetraspanin CD81 as a cellular receptor (Flint et al 1999). Interestingly, CD81 and
CD63 are thought to be in the same TEM. Additionally, these two proteases are
also believed to interact with and influence beta-1 integrin signaling
(Berditchevski & Odintsova 1999, Stetler-Stevenson 2008, Stipp & Hemler 2000).
Previous unpublished work in our lab indicated that beta-1 integrins might play a
role in NL63-CoV entry. Therefore these TEMs may play a role in HCoV entry
that awaits discovery. One interesting line of study would be to determine if
TMPRSS2 localization to these TEM regions is dependent on specific proteins,
such as the tetraspanins. As the protein webs can be formed by a series of
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protein-protein interactions, it would be interesting to identify the proteins
responsible for TMPRSS2 binding. Another path to follow would be to look if any
other HCoV entry factors are localized in TEMs. It is currently unknown if ACE2
or DC-SIGN, another putative entry co-factor for SARS-CoV, is associated with
any TEM (van Spriel & Figdor 2010). Perhaps these TEMs not only regulate
protease activity, but their coalescence directs substrate specificity.
4.2.4 TMPRSS2 relocalization
TMPRSS2 localization could be altered after SARS-CoV binding to the
host cell. Our initial experiments demonstrated that TMPRSS2 is required for
SARS S-mediated entry into Calu-3 cells. However, subsequent experiments
found that TMPRSS2 and ACE2 are not located near each other on the cell
surface and TMPRSS2 is not released into the apical mucus layer. Therefore,
TMPRSS2 or the ACE2-virus complex could diffuses across the membrane or
are both endocytosed together. In either case, the proteins will need to be in
close proximity to each other on the cell surface. To examine if ACE2 localization
is altered by virus binding, I bound virus to Calu-3 cells for different amounts of
time prior to immunofluorescent staining. However, the ACE2 staining pattern did
not change after virus binding (data not shown).
I next explored if TMPRSS2 was brought nearer to ACE2 after virus
binding. As ACE2 resides in lipid-rafts (Lu et al 2008), we used a biochemical
assay to look for TMPRSS2 relocalization to these lipid-rafts from the CD63
TEM. After one hour of virus binding, we noticed a shift of TMPRSS2 from non-
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raft to raft fractions, indicating that TMPRSS2 is brought nearer to ACE2 after
virus binding. This likely occurs on the cell surface because our assay only
probed for cell surface TMPRSS2 that was accessible to our membraneimpermeant biotinylation reagent. Therefore, TMPRSS2 is capable of cleaving S
after the virus has bound to ACE2. It would be interesting to visualize this
phenomenon through immunofluorescence. However, given that only a
proportion of TMPRSS2 is shifted, it would difficult to detect those few relocalized
proteins relative to the larger proportion in the TEMs.
4.3 Other host factors involved in HCoV entry
While most of this dissertation, and most CoV entry research in general,
focuses on receptors and proteases during virus entry, there are likely other
factors that influence CoV entry. As mentioned before, previous work in our lab
indicated that integrins might be important for NL63-CoV entry. Additionally,
another host protein, DC-SIGN, has been reported as a possible binding factor
for some HCoVs (Hofmann et al 2006, Yang et al 2004). While those are two
examples, they indicate that there are probably many unknown host factors
important for HCoV entry yet to be discovered.
4.3.1 Factors important in NL63-CoV entry
Unlike SARS-CoV, NL63-CoV grows poorly in tissue culture. In most cell
lines, NL63-CoV does not cause cell death and therefore is difficult to measure
infection. Recently, certain CaCo2 cell lines were found to be susceptible to
NL63-CoV induced cytotoxicity (Herzog et al 2008). However my research
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indicated that CaCo2 lines from different labs had different levels of cell death in
response to NL63-CoV. I hoped to compare the differences between these cell
lines to determine what cell factors are important for NL63-CoV-induced cell
death.
To examine these differences, I sought to create a recombinant virus with
a chimeric S comprised of the MHV-CoV transmembrane and internal portions
and external NL63-CoV portion. By using the transmembrane and cytoplasmic
tail of MHV-CoV S, I hoped the S would incorporate along with the rest of MHVCoV structural proteins. This idea was based on previous work identifying
regions within that portion S responsible for viral incorporation. However, I found
that the chimeric S did not incorporate into virus-like particles, indicating that it
probably is not found in infectious virions. While unexpected, this indicates that
the ectodomain of S must have some role in S incorporation, perhaps through
influencing the conformation of the other regions. In addition to its exclusion from
the virion, the chimeric S also was not capable of mediating membrane fusion. I
discovered this by confirming incorporation of the chimeric S into HIV-based
pseudoparticles that were then used to transduce receptor-bearing cells. The
pseudoparticles with the chimeric S were unable to mediate viral entry. This
finding was not wholly unexpected, as we knew that S1 and S2 interact in many
ways that are not fully understood. Perhaps the site selected for combination of
the NL63 S and MHV S somehow altered the refolding process of S during
fusion.
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As our attempts at creating a recombinant virus were unsuccessful, I could
investigate cellular factors important for NL63-CoV entry using a different
reporter system. In 2008, Donaldson et al. created a recombinant NL63-CoV
using a different molecular system (Donaldson et al 2008). This system divided
up the genome into smaller portions using type IIS restriction endonucleases and
pieced them together while incorporating either a luciferase or green fluorescent
protein reporter into the genome. Using this virus, I could infect the different
types of Calu-3 cells and measure entry into single cells or the entire cell
population. I could then create a heterokaryon of the different cell types to see if
a factor was missing that influence NL63-CoV entry and growth, or if there was a
dominant factor preventing NL63-CoV infection. Depending on that result, I could
perform a cDNA screen for factors that either inhibits growth in the permissive
cell or permits growth in the impaired cell. In theory, I could identify a factor, or
factors, important for NL63-CoV growth. Perhaps other HCoVs would also be
influenced by this factor, as most share similar fastidious growth.
4.3.2 Factors important for the host immune response
As previous work had indicated that much of the SARS-CoV induced
pathology was the result of an untoward cytokine response (Peiris et al 2003,
Rockx et al 2009), I set out to determine if entry specifically played a role in this
process. Some previous studies suggested that SARS-CoV entry could stimulate
the immune system (Chang et al 2004, Dosch et al 2009, Miura et al 2007, Wang
et al 2007, Yoshikawa et al 2009). As little was known about NL63-CoV induced
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cytokine responses I also explored that virus. Unfortunately, our preliminary
results were unable to be replicated. This finding could indicate that our
hypothesis was incorrect and SARS-CoV and NL63-CoV entry does not stimulate
cytokine release from respiratory epithelial cells.
One possible future direction of this work is to expand our experiments to
other cell lines. It is possible that SARS-CoV infection of pulmonary
macrophages could be the source of cytokine stimulation (Dosch et al 2009, Law
et al 2009, Wang et al 2007, Yoshikawa et al 2009). Using a cell line mimicking
macrophages, such as differentiated THP-1 cells, I could repeat the experiments
using the reagents already created. Understanding the immune response to
HCoVs is important for multiple reasons. The pathology of SARS-CoV suggested
that much of the disease was due to an unrestricted immune response and
cytokine storm (Frieman et al 2008, Peiris et al 2003, Rockx et al 2009).
Therefore, understanding the immune triggers during SARS-CoV infection is
imperative to understanding the resulting disease. Additionally, further studies
into the immune responses to other HCoVs could also prove useful in
understanding pathology, despite their milder clinical course. Much of the recent
work on MHV-CoV neuropathogensis has demonstrated a role for the immune
system in the pathology (Haring & Perlman 2001, Hosking et al 2010, Houtman &
Fleming 1996). Perhaps exploring immune responses to other HCoVs would help
elucidate mysteries surrounding the putative CoV-MS link.

95
4.4 Conclusions
Since their official recognition in 1968, CoVs have been found to be
increasingly important factors in human health. While much of the early research
into HCoVs was hampered by poor growth in tissue culture, modern techniques
are overcoming many obstacles. I now have cell lines that better mimic human
tissues, molecular mechanisms to create recombinant viruses, and sequencing
techniques to discover novel HCoVs. Using many of these techniques, this
dissertation set out to describe host factors important for HCoV entry. While one
important enzyme was described, TMPRSS2, there are many more yet
undiscovered. Therefore, it is our duty to use ever-evolving technologies to
continue our exploration, especially before the emergence of a new pandemic
HCoV.

APPENDIX:
SYNTHESIZED GENES
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SARS-RBD
GCG GCC GCA GCC ATG CCC ATG GGG TCT CTG CAA CCG CTG GCC
ACC TTG TAC CTG CTG GGG ATG CTG GTC GCT TCC GTG ATC ACC AAC
ATC ACC AAC CTG TGT CCC TTC GGC GAG GTG TTC AAC GCC ACC AAG
TTC CCG AGC GTG TAC GCC TGG GAG CGC AAG AAG ATC AGC AAC TGC
GTG GCC GAC TAC AGC GTG CTG TAC AAC TCC ACC TTC TTT AGC ACC
TTC AAG TGC TAC GGC GTT AGC GCC ACC AAG CTC AAC GAC CTG TGC
TTC AGC AAC GTG TAC GCC GAC AGC TTC GTG GTC AAG GGC GAC GAT
GTG CGC CAG ATC GCG CCC GGC CAG ACC GGC GTG ATC GCC GAC
TAC AAC TAC AAG CTG CCC GAT GAC TTC ATG GGC TGC GTG CTG GCC
TGG AAC ACC CGC AAC ATC GAC GCC ACG AGC ACC GGC AAC TAC AAC
TAC AAG TAT CGC TAC CTG CGC CAC GGC AAG CTG CGG CCC TTC GAG
CGC GAC ATC TCC AAC GTG CCC TTC AGC CCG GAC GGC AAG CCC TGC
ACG CCG CCC GCC CTG AAC TGC TAC TGG CCG CTG AAC GAC TAT GGC
TTC TAC ACT ACG ACC GGT ATC GGC TAC CAG CCC TAC CGC GTG GTC
GTG CTG AGC TTC GAG CTC CTG AAC GCG CCC GCC ACC GTG
ACAGGTAAGTATTAATTAATCGAT
NotI at N-terminus
ClaI at C-terminus
PacI
Green text: CD5 signal sequence from pCD8
Black text: codon-optimized NL63 RBD
Blue text: BclI site
Yellow highlight: altered to get rid of splice site
Blue highlight: last codon in RBD
Italic: splice site
Pink highlight: splice acceptor sites (0.65, 0.66)

[98]
NL63-RBD
GCGGCCGCAGCCATG CCC ATG GGG TCT CTG CAA CCG CTG GCC ACC
TTG TAC CTG CTG GGG ATG CTG GTC GCT TCC GTG ATC ACC CAG CAC
ACC GAC ATC AAC TTC ACC GCC ACG GCC AGC TTC GGC GGG AGC TGC
TAC GTC TGC AAG CCG CAC CAA GTG AAC ATC AGC CTG AAC GGC AAT
ACG AGC GTG TGC GTG CGC ACC AGC CAC TTC AGC ATC CGC TAC ATC
TAC AAC CGC GTG AAG AGC GGC AGT CCC GGC GAC AGC AGC TGG
CAC ATC TAC CTG AAG AGC GGG ACC TGC CCG TTC TCC TTC AGC AAG
CTG AAC AAC TTC CAG AAG TTC AAG ACG ATC TGC TTC AGC ACC GTG
GAG GTG CCC GGC AGC TGC AAC TTC CCG CTG GAG GCC ACC TGG
CAC TAC ACC AGC TAC ACC ATC GTG GGC GCC CTG TAT GTG ACC TGG
AGC GAG GGC AAC AGC ATC ACC GGC GTG CCC TAT CCC GTG TCC
GGC ATCACAGGTAAGTATTAATTAATCGAT
NotI at N-terminus
ClaI at C-terminus
PacI
Green text: CD5 signal sequence from pCD8
Black text: codon-optimized NL63 RBD
Blue text: NheI site
Blue highlight: last codon in RBD
Italic: splice site
Pink highlight: splice acceptor site (0.69)
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